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ABSTRACT 
REGULATION OF VASCULAR SMOOTH MUSCLE CELL 
PHENOTYPE 
Joshua K Salabei, 
October 30, 2012 
Vascular injury and chronic arterial diseases such as atherosclerosis and 
restenosis result in exposure of vascular smooth muscle cells (VSMCs) to 
increased concentrations of growth factors triggering a change from a contractile to 
a synthetic phenotype. The mechanisms by which growth factors trigger VSMC 
phenotype transitions remain unclear. Because phenotype switching involves the 
removal of contractile proteins, we hypothesized that autophagy is an essential 
modulator of VSMC phenotype. Also, the conversion to the synthetic phenotype is 
accompanied by cellular changes that trigger metabolic changes to meet the 
increasing demands for cellular energy. Little is known however about the 
contributions of different substrates metabolized for energy production and how 
these metabolic changes integrate with phenotype switching and VSMC 
proliferation. We further hypothesize that metabolic changes induced by PDGF are 
required for phenotype switching and proliferation. Studies presented here show 
v 
that: 1) Treatment of VSMCs with platelet-derived growth factor PDGF-BB results 
in activation of autophagy which is required for degradation of contractile proteins 
during phenotype switching; 2) Increased glycolytic flux caused by PDGF 
treatment is required for expression of the synthetic cytokine osteopontin and for 
proliferation; and 3) Mitochondria fragmentation and increased fatty acid oxidation 
are required for PDGF-induced VSMC proliferation. 
These results support the overall hypothesis that autophagy and changes in 
intermediary metabolic pathways are modulators of PDGF-induced phenotype 
transition. Our findings suggest that autophagy-directed therapies may provide 
effective treatments against vascular diseases such as atherosclerosis and 
restenosis. 
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ROLE OF VASCULAR SMOOTH MUSCLE CELLS IN VASCULAR DISEASES 
Despite advances in modern medicine, cardiovascular disease (CVD) remains 
the leading cause of mortality in the United States accounting for 35% of all 
deaths with about 1 in 3 American adults having one or more type of CVD [1]. 
According to the CDC, the total costs related to CVD in 2008 were in excess of 
$450 billion, and these are expected to increase in the future [1-4]. Although 
CVD-related deaths have declined in high income countries, mortality have 
increased in low and middle income countries [5]. These differences in mortality 
due to CVDs are attributable to modifiable risk factors such as healthy eating, 
exercise, air pollution, and smoking [6]. 
Cardiovascular diseases encompass all diseases affecting the cardiovascular 
system, which include the heart and peripheral blood vessels. One of the most 
common CVD is atherosclerosis, i.e., the buildup of cholesterol in the artery walls 
of blood vessels supplying the heart (coronary heart disease) or supplying the 
peripheral tissues (peripheral arterial disease) [7]. The onset of atherosclerosis 
begins early in life from childhood whereby there is a gradual deposition of 
cholesterol and oxidized low density lipoprotein (LDL) in the subintima of arteries 
leading to the formation of an atherosclerotic plaque. Plaque formation is caused 
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by macrophage-stimulated inflammatory reactions that ultimately leads to plaque 
rupture (or thrombosis) [8]. Thrombosis may lead to heart attack and/or stroke, 
which are ranked amongst the top three major causes of death in the United 
States [9]. 
Physiology of the healthy human artery: The mature healthy human artery is 
made up of 3 principal layers: the intima-composed of endothelial cells (ECs), 
the media-composed of primarily vascular smooth muscle cells (VSMCs) and 
the adventitia-composed of fibroblasts and connective tissues (Scheme 1). The 
complexity of the human artery has developed over time because the need for an 
efficient blood delivery system became needed as organisms became more 
complex. The different layers of the arteries have thus evolved to meet the needs 
of supplying oxygen and nutrients to distal organs and tissues. The endothelium 
is a thin layer of ECs allowing diffusion of important factors from blood to 
underlying layers and tissues. The media layer is found underneath the 
endothelium and it is composed of fully differentiated vascular smooth muscle 
cells, which express a repertoire of contractile proteins such as a-smooth muscle 
actin. Thus, the principal function of the media is contraction and regulation of 
vessel tone and blood flow. This layer is innervated by the sympathetic and 
parasympathetic nervous systems and therefore the regulation of this layer is 
tightly controlled [10-11]. Beneath the media is the adventitia, comprised mostly 
of fibroblasts and connective tissues. This layer provides mechanical support and 
stability to the blood vessels. 
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The formation of nascent blood vessels occurs via two processes; 
vasculogenesis, the formation of nascent blood vessels, and angiogenesis, the 
sprouting of new blood vessels from existing blood vessels. Expression of 
Vascular Endothelial Growth Factor (VEGF) is critical during vasculogenesis and 
angiogenesis [12]. VEGF-A stimulates the CD31+ and CD34+ VEGF receptor-
positive angioblasts to initiate vessel formation and set in motion molecular 
events that eventually lead to mature a vascular network [13]. VEGF-A stimulates 
angioblasts to differentiate into endothelial cells forming nascent tubes [14]. The 
endothelial layer in nascent tubes and mature blood vessels is usually a single 
cell thick, allowing for rapid exchange of materials between blood and underlying 
tissues. The nascent endothelial tubes formed after VEGF stimulation are 
stabilized by cells of the mural compartment, particularly VSMCs. Under the 
influence of platelet derived growth factor (PDGF) and other growth factors such 
as transforming growth factor 13 (TGF-I3), VSMCs form an outer layer beneath the 
endothelial cells. This stabilization is followed by extracellular matrix (ECM) 
deposition [15]. At the level of small arteries, i.e., arterioles, smooth muscle cell 
organization is relatively simple with a single smooth muscle cell wrapped 
completely around the lumen of the nascent endothelial tube [16]. In larger 
arteries where there are multiple smooth muscle cell layers, VSMCs are 
arranged close to perpendicular with the axis of blood flow [16]. This 
arrangement aids lengthening of blood vessels during high pressure thus 
regulating vessel tone and blood distribution. Beneath the media layer of VSMCs 
is the adventitia layer composed of fibroblasts and other ECM components. The 
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main function of the adventitia is structural because it attaches the blood vessel 
to the basement membrane; however, the adventitia is increasingly recognized to 
play non-structurally related functions because changes in this layer were 
amongst the earliest structural changes found in diseased vessels [17]. 
Atherosclerosis involves the buildup of cholesterol and oxidized LDL in the 
artery wall: During atherogenesis, accumulation of cholesterol and oxLDL in the 
subintima space of the artery [18-19] leads to recruitment of monocytes (from 
the circulation) through cell junctions of the endothelial layer into the subintimal 
space [16-17] (Scheme 2). In the subintima, monocytes differentiate into 
macrophages and continuously take up excess lipids while failing to return into 
circulation (i.e., impaired efferocytosis). This repeated failure of the innate 
immune responses to clear subintimal LDL results in the deposition of lipid-
loaded macrophages (foam cells) which in turn induces vascular inflammation in 
the vessel wall [20]. Foam cell formation is also thought to occur through VSMC 
engulfment of subintimal lipids [21-22]. Most often, lesions are covered and 
stabilized by VSMCs which are thought to migrate from the media layer to form a 
neointima or protective cap [21-22]. However, continuous failure to clear foam 
cell macrophages and increased vascular inflammation beneath such caps 
progressively leads to weakening of the protective cap. Such advanced lesions 
when present in areas of high stress, for example in arterial branches, often lead 
to plaque rupture and thrombosis leading to heart attack or stroke. 
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Scheme 1 
Cross sectional area of a human artery 
5 
The majority of atherosclerotic lesions in humans go unnoticed because of the 
formation of the neointima that covers and stabilizes these lesions [23]. In cases 
where the formation of the neointima is thick enough to hinder blood flow through 
a vessel, slight chest pain or angina is often felt [24]. In other cases where there 
is severe or complete obstruction of blood flow (such as after thrombosis), 
angioplasty, a mechanical surgical intervention, is used to widen the obstructed 
artery after which a (drug eluting) stent is placed to prevent VSMC proliferation. 
However, re-occlusion (or restenosis) of previously opened (restored) arteries 
characterized by excessive proliferation of underlying VSMCs that migrate 
luminally and form a neointima is common [25-26]. For example, a study with a 
total of 1,012 patients who were randomly assigned treatment with sirolimus-
eluting (n = 503) or paclitaxel-eluting stents (n = 509) showed that -28% of 
subjects needed revascularization at some later time [27]. Although the outcome 
of such clinical studies depends on the demographics of the population in 
question (such as the presence of diabetes), it highlights restenosis as an 
important question that continually warrants our attention. Endothelial damage 
caused by angioplasty or diseased conditions is thought to cause increased 
exposure of underlying VSMCs to growth factors such as PDGF and other 
cytokines resulting in their migration (from the media) and hyperproliferation in 
the neointimal region [28]. Currently, drug-eluting stents (DES) are often placed 
in arteries after the plaque has been cleared, the goal of which is to inhibit VSMC 
proliferation and restenosis. However, despite these interventions, restenosis 
continues to be problematic especially in certain classes of patients such as 
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those suffering from diabetes, where the restenotic process is more severe, often 
leading to increased neointima formation and total vessel occlusion [29-31]. This 
can result in increased incidence of myocardial infarction, heart failure [32] and 
vasculopathy, which contribute significantly to morbidity and mortality ascribed to 
diabetes [33-35]. 
Phenotype switching in VSMCs: VSMCs in healthy arteries express a 
repertoire of contractile proteins, signaling molecules and ion channels required 
for their contractile function [36]. A number of SMC-specific contractile genes 
have been used to identify the contractile phenotype. These include smooth 
muscle isoforms of a-actin (SM-a-actin), SM myosin heavy chain (SM-MHC), 
calponin, SM22a and smoothelin [37-45]. Although these SMC marker genes are 
expressed in the differentiated phenotype, they are also transiently expressed in 
other cell types during development, disease progression and tissue repair [46]. 
Because of this, multiple marker genes are required for rigorous identification of 
fully differentiated VSMCs, and no one SMC marker gene can exclusively be 
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Unlike skeletal and cardiac muscle cells, which are terminally differentiated [47], 
VSMCs have a unique characteristic of plasticity that enables them to switch to a 
less contractile or synthetic phenotype (de-differentiation). The synthetic 
phenotype is typically characterized by loss of expression of contractile proteins 
and increased expression of synthetic proteins such as osteopontin [28, 48]. 
However, there appears to be a phenotype gradient between the contractile and 
synthetic phenotypes, such that, depending on environmental cues, VSMCs can 
develop features of both phenotypes or reverse their phenotype from a de-
differentiated to a contractile phenotype [49]. 
Many factors regulate the development or maintenance of the contractile and 
synthetic phenotypes. Some of these factors have been summarized in Table 1. 
Synergistic effects of signals or synergistic effects of multiple pathways on VSMC 
dedifferentiation have also been reported. For example, it was shown that PDGF 
and IL 1-13 can act synergistically to promote the development of the synthetic 
phenotype [50]. Extracellular matrix proteins such as polymerized collagen have 
been shown to cause down regulation of genes such as thrombospondin and 
fibronectin, which are known to be upregulated in injured vessels [51]. Other in 
vitro studies have further confirmed that VSMCs cultured on a fibronectin coated 
surfaces are induced to become more synthetic, while when cultured on a 
laminin-rich surface, their contractile phenotype is maintained [52-53]. The 
effects of these different ECM proteins on VSMC phenotype is known to be 
mediated through integrin-cell surface receptors. Wang et al [54] showed that the 
ECM cartilage oligomeric matrix protein (COMP) maintained VSMCs in their 
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contractile phenotype and the effects of COMP were mediated through 07131 
intergrin, a major laminin receptor in VSMCs. The role of growth factors in 
regulating VSMC phenotypes has also been extensively studied. Transforming 
growth factor beta, insulin growth factor-1 and angiotensin are known examples 
that promote the contractile phenotype (see Table 1). In contrast, basic fibroblast 
growth factor (bFGF) and PDGF promote the synthetic phenotype, although only 
PDGF has been identified as a factor that can selectively and directly promote 
phenotypic modulation of VSMCs [55-56]. 
PDGF as a mitogen and an inducer of VSMC phenotypic switching: The 
platelet derived growth factors (PDGFs) constitute key mitogens for cell types of 
mesenchymal origin including smooth muscle cells. The PDGFs comprise a 
family of four different polypeptides, which include PDGF-A, B, C and D. These 
polypeptides form homo- or hetero-dimers with five known dimeric isoforms: 
PDGF-AA, AB, BB, CC and DD. PDGF-A and B are known to heterodimerize 
while PDGF-C and D only form homodimers [57] (Scheme 3). The PDGFs signal 
through tyrosine kinase receptors, i.e., PDGFR-o and PDGFR-I3. Both PDGFR-o 
and -13 can form homo or heterodimers that can be activated to varying degrees 
by the PDGFs [57]; however, PDGF-BB has been shown to be one of the most 
potent forms to activate the PDGFR signaling cascade, leading to VSMC 
dedifferentiation and proliferation [58]. PDGF-BB, to date, is the most potent 
stimulator of VSMC proliferation, migration and phenotype switching [56]. 
10 
Factor 




• PDGF-BB • Promotes synthetic • [58-59] 
• bFGF • Promotes synthetic • [60-61] 
• Angiotensin II • Promotes contractile • [62] 
• Transforming growth factor • Promotes contractile • [63-64] 
• Insulin and IGF-1 • Promotes contractile • [65] 
Injury/atherogenic stimuli 
• Promotes synthetic • [66-67] • Oxidized phospholipids 
• ROS 
• Promotes contractile • [68] 
• Cytokines • Promotes synthetic • [50,69] 
MicroRNAs 
• miRs 145, 143, 195, 25, 1 • Promotes contractile • [70-74] 
• miRs 21,221,222,126 • Promotes synthetic • [75-76] 
Basement matrices 
• Monomeric collagen • Promotescontractile • [50] 
• Polymeric collagen • Maintains contractile • [50] 
• Fibronectin • Promotes synthetic • [77] 
• Matrigel • Promotes contractile • [78] 
Extracellular matrix components 
• Promotes synthetic • [79] • ADAMST7 
• Cartilage oligomeric matrix protein • Maintains contractile • [80] 
• Osteopontin • Promotes synthetic • [81] 
Pharmocoligical inhibitors 
• Promotes contractile • [82-83] • Rapamycin • Promotes contractile • [84] • Lovastatin 
Promotes contractile • Unpubli 
• Spautin1 • shed 
Table1: Factors regulating VSMC phenotypes 
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PDGF signals via multiple pathways: In the VSMC, PDGF-BB signals 
principally through PDGFR-j3j3 and activates several biological pathways 
responsible for VSMC growth and dedifferentiation [85]. These pathways have 
also been shown to play a role in the pathogenesis of diseases such as 
atherosclerosis and restenosis [49]. PDGF-BB activates the Akt, Erk1/2 and p38 
MAPKs, as well as the JNK pathways. Activation of the Erk1/2 and Akt pathways 
is known to play important roles in PDGF-induced VSMC proliferation, migration 
and phenotype switching [50]. The activation of the other MAPKs by PDGF also 
has profound effects on SMC behavior. Zhan et al [86] infected VSMCs with Ad-
DN-p38 or Ad-DN-JNK and found that PDGF-induced SMC migration was 
suppressed by 81 %, and 77%, respectively. Zhan et al also showed that Ad-DN-
p38 inhibited neointima formation after balloon injury of a rat carotid. This role of 




PDGF-AA PDGF-CC PDGF-AB PDGF-DD PDGF-BB 
PDGF receptor type 
Platelet derived growth factors and platelet derived growth factor receptors 
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Multiple pathways and transcription factors are required for PDGF-induced 
phenotype switching and proliferation: PDGF-BB-induced phenotype 
switching in VSMCs occurs, in part, through transcriptional regulation of 
promoters upstream of SMC marker genes resulting in their down regulation. A 
critical transcription factor controlling expression of VSMC marker genes is 
serum response factor (SRF). SRF binds to CC(AIT-rich)6GG (CArG) boxes in 
the promoter regions of VSMC marker genes to control their expression [88]. 
CArG boxes are also present in the promoter regions of genes involved in ECM 
production, migration and proliferation of VSMCs [89]. This suggests that any 
factor that affects SRF binding to its response element is likely to affect multiple 
genes that regulate cell phenotype. SRF utilizes coactivators such as myocardin, 
which is expressed exclusively in SMCs and cardiomyocytes [90]. Generally, 
myocardin forms a complex with SRF on CArG boxes to promote contractile 
gene expression [90] (Scheme 4). In its simplest model, SRF is seen as a 
platform molecule that, when bound to the CArG box, recruits other molecules to 
form complexes. These complexes either activate or suppress expression of 
SMC marker genes. PDGF is known to suppress complex formation of 
myocardin and SRF and thus promotes the down regulation of contractile gene 
expression [91] (Scheme 4). Simultaneously, PDGF promotes complex formation 
of SRF with other transcription factors such as Elk-1, which is also known to play 
a role in down regulating VSMC contractile gene expression [91]. 
Another important transcription factor known to play a role in PDGF-induced 
VSMC dedifferentiation is Kruppellike factor 4 (Klf4) [92-95]. Klf4 is up-regulated 
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upon PDGF stimulation, and siRNA suppression of Klf4 was shown to inhibit 
PDGF-induced down-regulation of contractile genes [96]. This regulation of 
transcription factors is one level of control regulating VSMC phenotype switching. 
CArG boxes in promoter regions are epigenetically marked with distinctive 
patterns of posttranslational modifications in the form of histone methylations and 
acetylations [58, 97]. These modifications regulate cis and trans DNA elements 
also necessary for the control of expression of smooth muscle cell marker genes 
[98]. In addition to regulating transcription factors, PDGF-BB is also known to 
alter these posttranslational modifications through decreased histone (H4) 
acetylation [99]. 
Phenotype switching induced by PDGF is accompanied by changes in ECM 
components: The synthetic phenotype of VSMCs is characterized by increased 
ECM secretion which is known to play an important role during cap formation in 
atherosclerosis [36]. During phenotype switching, PDGF induces changes in 
ECM components such as MMPs [100] and plasminogen activator inhibitor 
protein 1 (PAI-1) [86]. An important class of MMPs affected by PDGF and known 
to affect the progression of atherosclerosis and restenosis is the disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS). Members of the 
ADAMTS family bind to and degrade other ECM components. ADAMTS-7, in 
particular, increases after balloon injury of the carotid artery, and its 
overexpression exacerbates neointima formation [101] (see Table 1). An 
important ECM protein degraded by ADAMTS-7 is COMP (or cartilage oligomeric 
matrix protein) [102]. Unlike ADAMTS-7, COMP expression decreases after 
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balloon injury and its overexpression inhibits neointima formation [102]. COMP is 
known to interact with the integrin receptor a7131 thereby indicating that the 
intergrin receptors play important roles during PDGF-induced VSMC changes. 
The alteration of the ECM also serves the purpose of releasing growth factors 
and promoting VSMC migration during vascular remodeling under pathology. 
PDGF-induced osteopontin expression is important in VSMC remodeling: A 
key synthetic gene in the context of vascular disease induced upon PDGF 
stimulation is osteopontin (OPN) [103]. OPN is also known as bone sialoprotein 
1 (8SP-1) or secreted phosphoprotein 1 (SPP1) and is secreted by other cell 
types like macrophages and endothelial cells [104]. OPN is a cytokine with 
autocrine effects and is thought to play important roles in VSMC proliferation 
during atherosclerosis [105]. Its levels are also increased during neointima 
formation [103, 105-106]. In fact, it has been shown that ablation of OPN in 
female APOF'- mice completely prevented the formation of atherosclerotic 
plaques [107]. Leali et al [108] showed that overexpressing OPN prevented re-
endothelization via intergrin engagement and that endothelial cells grown on an 
OPN-rich basement showed reduced wound healing [108]. OPN is also 
associated with aortic abdominal aneurysm (AAA), the weakening and bulging of 
blood vessels due to excessive apoptosis of VSMCs in the media. Using 
microarray analysis, Zheng et al [109] found that OPN was the highest expressed 
gene in AAA tissues collected from patients who had no atherosclerosis but 
underwent AAA repair operations. Zheng and colleagues found that OPN 




Platelet-derived growth factor-BB 
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led to type II cell death of VSMCs. The autophagy induced by OPN was 
mediated through an integrin/CD44 and p38 MAPK-mediated pathway [11 OJ. 
In patients suffering from diabetes, OPN is known to playa role in increased 
vascular calcification. It has been proposed that the metabolic alterations of 
diabetes are responsible for the increase in vascular calcification in these 
patients [111-112]. Because dysregulated glucose metabolism plays a key role in 
the development of diabetes, it was hypothesized that glucose regulates OPN 
expression. Based on this hypothesis and using gel mobility shift assays, Bidder 
et al [113] identified upstream stimulatory factor (USF) and activator protein-1 
(AP1) as important regulators of OPN gene expression. The levels of USF and 
AP1 were in turn controlled by glucose metabolism. Mannitol and 2-
deoxyglucose failed to produce the same effects. A few years later, Berglund et 
al [114] specifically implicated the role of nuclear activator of T cell (NFAT) in 
hyperglycemia-dependent regulation of OPN expression in VSMCs. These 
studies suggest that glucose metabolism plays a key role in OPN expression and 
perhaps in PDGF-induced OPN gene induction. How glucose metabolism 
regulates OPN expression remains unclear. 
Evidence of phenotype switching in atherosclerosis and restenosis: Several 
studies support the idea that conversion of smooth muscle cells to a synthetic 
phenotype plays an important role in vascular disease. For example, time 
dependent down regulation of a-sm-actin was observed in autopsied tissue 
samples from atherectomy patients and from patients undergoing transluminal 
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coronary angioplasty indicating that there was at least some change in SMC 
phenotype different from the contractile found in healthy blood vessels [115-116]. 
This finding in humans was later reproduced in experimental models of rabbit 
atherosclerosis. Aikawa et a/ [117] found that contractile genes were down 
regulated in the media and outermost edge of atheromas in these animals. The 
expression of these contractile genes showed a time dependent increase in 
experimental groups undergoing extensive lipid lowering treatment for 16 months 
after induction of atheroscelerosis. This suggests that SMCs became more 
contractile after lipid lowering and this corresponded to decreased 
atherosclerosis. A profound finding in this study is that the lipid lowering 
treatment caused marked reductions in ECM proteins such as MMPs and 
VSMCs acquired an appearance of the contractile phenotype characterized by 
few secretory organelles such as the golgi and endoplasmic reticulum. 
Further supporting a role of phenotypic remodeling, other studies have reported 
that intimal SMCs undergo changes such as increased DNA synthesis, 
expression of proliferating markers such as PCNA and cyclins, decrease 
expression of contractile genes (other than a-sm-actin) and alteration of cell 
ultrastructure [118-120]. In 2001 it was shown that pharmacological inhibitors of 
PDGF receptors could inhibit VSMC proliferation, migration and neointima 
investment [121]. This experiment was not conclusive in providing clear evidence 
as to the role of PDGF in atherosclerosis because the unwanted side effects of 
the use of chemical inhibitors could not be rigorously ruled out. Later in 2002, 
using a different approach, a direct role of PDGF-induced phenotypic modulation 
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began emerging clearly. Kozaki ef al [122] administered PDGFR blocking 
antibodies to ApoE-I- mice on a Western diet and found that there was up to 67% 
reduction in atherosclerotic lesion size with reduced SMG investment in the 
neointima. 
The majority of studies have thus focused on identifying signaling and 
transcriptional mechanisms regulating phenotype switching in diseased 
conditions. For example, Wamhoff ef al [123] showed that mutation of a GIG 
repressor in the 5' region of the GArG element of SM22a promoter and other 
SMG marker gene promoters abolished the downregulation of SMG marker 
genes in ApoE-I- mice on Western diet. The GIG repressor binds to the 
transcription factor KLF4 and interestingly PDGF-induced SMG marker gene 
repression is dependent on KLF4 binding to the GIG repressor [66, 92]. In ApoE-
1- animals on Western diet, KLF4 expression was markedly increased within 
lesions [67]. Also, KLF4 overexpression strongly inhibited the expression of 
myocardin, the coactivator necessary for SMG marker gene expression 
meanwhile conditional knockdown of KLF4 transiently delayed the repression of 
SMG marker genes in ApoE-I- animals on high fat diet [124-125]. These findings 
therefore suggest a hypothesis whereby PDGF-induced phenotype switching 
during atherogenesis occurs via KLF4 binding to the GIG repressor of SMG 
marker genes thereby causing repression (Scheme 4). Few studies have looked 
at postranscriptional changes such as protein degradation and how these 
changes could impair phenotype switching. 
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Protein degradation during phenotype switching and in vasculo-proliferative 
disorders: In order to maintain homeostasis, mammalian cells need to balance 
synthetic and degradative processes. Cellular degradation in mammalian cells is 
carried out by two well described mechanisms: the proteasomal and autophagic 
pathways [126-128]. 
Few studies addressing the role of the proteasomal pathway in vascular smooth 
muscle cell remodeling and proliferation during arterial disease have been 
reported. For example, the proteasomal inhibitors lactalysin and MG132 inhibited 
VSMC proliferation in culture and after arterial injury in an animal model of 
restenosis [129-130]. These inhibitors were found to stall cells at the S-phase of 
cell cycle probably through up-regulation of the cell cycle inhibitor p21. However, it 
has not been determined whether these drugs inhibited phenotype switching, 
which is generally thought to precede VSMC proliferation. 
The role of autophagy in atherosclerosis has also been documented. For example, 
it was recently reported that inhibiting autophagy in macrophages by silencing 
ATG5 or other autophagy mediators led to both increased apoptosis and plaque 
instability in advanced lesions [131-132], which increases the risk of MI. Perhaps, 
ablation of autophagy in these macrophages led to the accumulation of damaged 
materials (e.g., misfolded proteins, damaged mitochondria) that triggered 
apoptosis. Such a finding indicates a beneficial role of autophagy in atheroclerosis. 
Autophagy is known to playa protective role in the VSMC in lesions. For example 
autophagy is known to be protective against cholesterol and HNE-induced toxicity 
[133-134]. Autophagy was found to be responsible for the degradation of protein-
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HNE adducts thus increasing the survival of VSMCs. However, the response to 
HNE-induced toxicity or HNE-protein adduct formation in the different phenotypic 
states has never been thoroughly studied. Since synthetic VSMCs are the 
abundant phenotypes present in atherosclerosis, a prediction will be that these 
synthetic VSMCs are more resistant to oxidative insults, thus explaining their 
survival in this harsh oxidative environment. Also, since there is rapid turnover 
during phenotype conversion, autophagy might serve the purpose of degrading 
cellular components, releasing metabolic intermediates needed by the 
metabolically demanding synthetic cell [135]. 
PDGF-induced phenotype switching and proliferation is accompanied by 
metabolic changes: Proliferating cells require, in addition to ATP, large amounts 
of nucleotides, amino acids and lipids. Glucose and glutamine are principal 
substrates used for the production of ATP as well as intermediates critical for the 
synthesis of important biomolecules [136-137]. Although the hydrolysis of ATP is 
needed for important biochemical reactions important during proliferation, 
additional requirements also have to be met. For example, synthesis of fatty 
acids requires more equivalents of carbon and NADH than of ATP [138]. Total 
metabolism of a glucose molecule can generate up to 36 ATPs. This number of 
ATP molecules far exceeds the amount needed to synthesize 1 molecule of an 
amino acid or a fatty acid like palmitate. For this reason, the bulk of glucose 
catabolism in proliferating cells cannot be solely committed for ATP production. If 
this were the case, the resulting rise in ATP/ADP ratio would ultimately decrease 
the flux of glucose into the glycolytic pathway and the production of key glycolytic 
22 
intermediates needed for the production of other biomolecules by the proliferating 
cells would be severely impaired. 
Thus, it is clear that some of the glucose has to be diverted for the formation of 
macromolecular precursors such as acetyl-GoA needed for fatty acid synthesis. 
For example, during fatty acid synthesis, glucose is converted to acetyl-GoA 
which is then used to synthesize citrate in the TGA in the mitochondria. The 
citrate molecule is then transported back into the cytosol where the acetyl-GoA is 
recaptured and used to add 2 carbons to the growing fatty acid chain. This 
reaction occurs under conditions of high ATP/ADP ratio such as found in 
proliferating cells. For such reasons, during proliferation, the metabolism of 
glucose is tightly controlled and orchestrated to support the production of key 
metabolic intermediates needed for biomolecular synthesis. This control is 
achieved through growth factor signaling which regulates the activity of glycolytic 
enzymes such as pyruvate kinase and modulates flux of carbon through the later 
steps of glycolysis [139]. For example, signaling through the PI3K pathway is 
linked to protein synthesis and glucose uptake and utilization. PI3K signaling 
through Akt can regulate expression of glucose transporter, and has been shown 
to have direct effects on enzymes such as hexokinase and phosphofructokinase 
activity [140-142]. Small molecule inhibitors that inhibit PI3K signaling also lead 
to inhibition of glucose uptake and utilization and proliferation [143]. The process 
of inhibition growth factor signaling has been the principal mechanism employed 
to interrupt aberrant proliferation of cells under disease states. 
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In the VSMCs, PDGF signals through the PI3K pathway to increase flux in 
glycolysis and induce proliferation [144]. This increase in glycolytic flux caused 
by PDGF depends on enhanced glucose uptake because when glucose in the 
media was replaced with 2-deoxyglucose, glycolysis and proliferation were 
inhibited [145]. These and several studies have thus focused on the inhibition of 
PDGF signaling and glucose utilization in order to inhibit VSMC proliferation. 
PDGF-induced glycolysis has been shown to provide substrates to the 
mitochondria, increasing basal oxygen consumption while also enhancing 
mitochondria reserve capacity [145]. The induction of proliferation by PDGF was 
found not only to be dependent on increased glycolytic flux, but also on 
increased LDH activity because LDH expression was increased and because L-
lactate could support PDGF-induced proliferation in the absence of glucose 
[145]. These findings thus suggest that integrated coordination of glycolysis and 
mitochondrial metabolism is required for PDGF induced proliferation, although 
very few studies have interrogated the role of the mitochondria after PDGF 
stimulation with respect to proliferation. Also, since phenotype switching induced 
by PDGF is an energy expending process, it is of interest to determine the role 
glucose metabolism plays during phenotype switching. How mitochondrial 
metabolism and dynamics integrates with phenotype switching and proliferation 
after PDGF stimulation warrants our attention. 
Thus, the work presented was undertaken to: 1) Determine the role of autophagy 
in phenotype switching induced by PDGF; 2) Determine the role of glucose 
metabolism in PDGF-induced phenotype switching and proliferation; and 3) To 
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test whether changes in mitochondria dynamics regulates VSMC phenotype 
switching and proliferation. 
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PROJECT OBJECTIVE 
The goal of my research is to better understand the mechanisms that regulate 
the VSMC phenotype in the context of vascular disease. I hypothesize that 
controlled and synchronized changes in metabolism influence or coordinate 
cellular programs to elicit changes in SMC structure and function. Specifically, I 
posit that changes in cell function, such as those occurring during the contractile-
to-synthetic phenotype switch, require activation of protein degradation 
programs, such as autophagy, to remove contractile proteins and to re-structure 
the cell to perform specialized secretory functions. Specific aims to address the 
aforementioned hypothesis were 1) To examine protein degradation pathways 
involved during phenotype switching; 2) To determine the role of glucose 
metabolism with respect to phenotype switching and 3) To examine the role of 
mitochondria remodeling and substrate usage during phenotypic switching. A 
significant portion of my research was directed toward understanding the role of 
protein degradation mechanisms involved in growth factor-induced phenotype 
conversion (Chapter II). These studies have elucidated an exciting new role of 
autophagy in the regulation of the VSMC phenotype by showing that PDGF 
activates a unique type of autophagy that regulates the abundance of contractile 
proteins. 
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Our studies have also addressed the role of metabolism in VSMC 
hyperproliferative responses, such as occurs in injured vessels, where alterations 
in pathways of intermediary metabolism may impact the proliferation of VSMCs 
upon stimulation with growth factors. As described in Chapter III, my studies 
identify a key role for glucose metabolism pathways in the regulation of the 
synthetic protein osteopontin. Furthermore, in Chapter IV, we found that 
conversion to the synthetic phenotype is associated with mitochondrial 
fragmentation and a switch to fatty acid oxidation, which appear to play critical 
roles in inducing the proliferative phenotype. Collectively, these cooperative 
changes in metabolism integrate to promote the development of the synthetic 
VSMC phenotype. These findings provide novel and fundamental insights that 




PDGF-MEDIATED AUTOPHAGY REGULATES VASCULAR 
SMOOTH MUSCLE CELL PHENOTYPE TRANSITION AND 
RESISTANCE TO OXIDATIVE STRESS INDUCED BY HNE 
I ntrod uction 
Vascular smooth muscle cells (VSMCs) are essential regulators of vascular 
function. In healthy arteries, VSMCs are located in the medial vascular layer, 
where they express a repertoire of contractile proteins that help to regulate vessel 
tone and blood flow [36]. During atherogenesis and arterial restenosis, VSMCs 
change from a contractile phenotype to a synthetic phenotype. This promotes their 
migration to the intima, increases their proliferative capacity, and promotes the 
synthesis of extracellular matrix proteins [146]. These changes in VSMC 
phenotype appear to be fundamental in regulating the composition and stability of 
vascular lesions [147]. 
While several factors have been suggested to mediate VSMC phenotype 
transitions, platelet-derived growth factor (PDGF) is among the most robust 
phenotype-modulating agents and has been shown 
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to be a primary regulator of smooth muscle cell growth and proliferation. It has 
been shown that antibodies against PDGF [148-150] or PDGF receptors [151-152], 
antisense oligonucleotides to PDGF receptors [153-154], or PDGF aptamers [155] 
inhibit smooth muscle accumulation in the intima after balloon injury, and VSMCs 
lacking PDGFR-(3 show strikingly diminished neointimal accumulation after carotid 
artery ligation [156]. Moreover, pharmacological inhibition of PDGF Signaling 
reduces VSMC proliferation, migration, and occupancy in the neointima [157-159]. 
Hence, understanding how PDGF regulates VSMC phenotype may be essential for 
developing better and more targeted strategies for preventing or ameliorating 
vascular disease. 
The switch from the contractile to the synthetic VSMC phenotype induced by 
PDGF is initiated upon PDGF binding to surface receptors, which activate several 
intracellular signaling pathways that ultimately regulate gene expression and 
cellular function. These signaling pathways have been shown to result in 
decreased abundance of contractile proteins and increased expression of synthetic 
proteins such as osteopontin [36, 106] and vimentin [160-161]. Such structural 
changes have been shown to be prerequisites for enhanced cellular proliferation of 
VSMCs in culture [162]. Although multiple studies have focused on identifying the 
molecular mechanisms involved in phenotype switching [36, 146], it remains 
unclear how VSMCs can rapidly change from the contractile to the synthetic 
phenotype. Previous work from our laboratory has shown that autophagy is 
activated in VSMCs to remove oxidatively damaged proteins [133], which can form 
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large aggregates that are particularly difficult to digest. This suggested to us that 
the contractile apparatus, which must be removed during cellular transition to the 
synthetic phenotype, may also be degraded by autophagy and that autophagy 
might be an essential regulator of VSMC viability in diseased vessels. Therefore, 
we examined whether PDGF-induced transition from the contractile to the synthetic 
phenotype is accompanied by an increase in autophagy and whether stimulation of 
autophagy is required for phenotype switching. Our results support the notion that 
autophagy is essential for the conversion of VSMC from a contractile to a synthetic 
phenotype and that this increase in autophagy in synthetic cells could also function 
to prevent cell death due to oxidative stress. 
Experimental Procedures 
Materials: Antibodies against a-smooth muscle cell-actin (a-SMA), calponin and a-
tubulin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Osteopontin 
antibody was purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA). 
Recombinant FGF-1 was obtained from eBiosciences (San Diego, CA, USA). 
Antibodies against GAPDH, p-AktlAkt, p-p70S6K1p70S6K, p-AMPKIAMPK and p-
mTOR/mTOR and LC3 were purchased from Cell Signaling (Danvers, MA, USA). 
Recombinant rat PDGF was obtained from R&D Biosystems (Minneapolis, MN, 
USA). HRP conjugated rabbit and mouse IgG secondary antibodies were obtained 
from Cell Signaling Technologies (Danvers, MA, USA). The 3-methyladenine (3-
MA), epoxomicin, and bafilomycin A 1 were obtained from Sigma-Aldrich. Goat anti-
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mouse IgG-Alexafluor 555 was obtained from Invitrogen (Grand Island, NY, USA). 
Spautin-1 was obtained from Cellagen Technology (San Diego, CA, USA). Ad-GFP 
and Ad-GFP-lC3 were obtained from Vector Biolabs (Philadelphia, PA, USA). All 
primers used for real time PCR were designed using the primer express software 
from Applied Biosystems (Carlsbad, CA, USA) and then ordered from Integrated 
DNA Technologies (Coralville, lA, USA). DAPI stain was obtained from Invitrogen. 
Electrophoresis supplies were purchased from Bio-Rad (Hercules, CA, USA). 
ECl ® reagents were purchased from GE Healthcare (Pittsburgh, PA, USA). 
Vascular smooth muscle cell isolation: Up to 3 extracted aortas from 6-week-
old male Sprague-Dawley rats were cleaned to remove all perivascular fat. Sterile 
capel blades were used to minced aortas in a culture dish containing DMEM and 
1 % PIS. The minced aortas were then transferred into sterile 50ml tubes. Enzyme 
solution (0.1% collagenase type 1A, 0.05% elastase type III, 2mg/ml BSA, and 
2mM calcium chloride) made in DMEM containing 1 % PIS was then added to the 
minced aortas and incubated for 1 h (at 37°C containing 5% CO2). The enzyme 
solution was mixed regularly during incubation. After digestion, supernatant was 
carefully removed and discarded. Chunks of tissues at the bottom of the tube were 
transferred into a new sterile tube and 5ml of fresh enzyme solution added and 
digestion carried out for about 3 h while monitoring degradation of tissue. Growth 
media (5 ml) was added immediately after all tissue was degraded and the entire 
content centrifuged for 5 min at 1100 rpm at 4°C to pellet cells. After centrifugation, 
supernatant was discarded followed by addition of more growth medium and 
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another round of centrifugation. After the 2nd centrifugation, cells were 
resuspended in growth media, counted and plated at a density of 0.4-0.6x1 06 cells 
per 25cm2 flask containing 2.5 ml DMEM + 10%FBS + 1 %P/S. Cells were split 
when 75% confluency was achieved. 
Cell culture: Isolated VSMCs were grown in DMEM (Dulbecco's modified Eagle's 
medium; Life Technologies-Invitrogen) supplemented with 10% (v/v) FBS (fetal 
bovine serum; Atlanta Biologicals, Atlanta, GA, USA) and 0.1 % 
streptomycin/penicillin. Only cells that stained positive for calponin and a-SMA 
were used in experiments. To ensure maintenance of the contractile phenotype, 
only cells between passages 2-7 were used. Cells were maintained in a humidified 
atmosphere of air and 5% CO2 at 37 cC. At -70% confluency, VSMCs were serum-
starved in DMEM containing 0.1 % FBS for 24 h. After desired treatments, cells 
were rinsed twice with phosphate-buffered saline and then lysed in a protein lysis 
buffer containing 25 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.1 % SDS, 1 % NP-
40, and 1X protease and phosphatase inhibitors. The Lowry DC assay (Biorad, 
City, St., USA) was used for measuring protein concentration of crude cell extracts. 
Messenger RNA isolation and real-time PCR: Messenger RNA was isolated 
from RASMCs using TRIZOL reagent (Invitrogen) and the concentration was 
determined by measuring absorbance at 260nm using a Nanodrop 
spectrophotometer (Thermo scientific). A 20 IJI reverse transcription reaction 
mixture containing 1 IJg mRNA, 10 units AMV reverse transcriptase, 0.4 IJM poly T 
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primer (dT18), 0.2 mM dNTPs, and 20 units RNasin (Promega) was subjected to 
complimentary DNA (cDNA) synthesis in a thermal cycler (BioRad). Two 
microliters of cDNA was then used for amplification of the gene of interest by real 
time PCR using SYBR green (VWR, Radnor, PA, USA). 
Western blotting: Approximately 0.5-25 I-Ig of crude cell protein was applied to 
each lane of a 10.5-14% Bis-Tris-HCI gel and electroblotted onto a PVDF 
membrane. The membrane was then incubated overnight at 4°C using appropriate 
dilutions of primary antibodies. PVDF membranes were then incubated at room 
temperature with horseradish peroxidase-conjugated secondary antibodies. 
Immunoreactive bands were detected using a typhoon scanner (SA Biosciences, 
Valencia, CA, USA) after exposure to ECl detection reagent. Bands intensity was 
quantified by using the Totallab Tl120 software. 
Measurement of protein-bound HNE: VSMCs were serum-starved for 24 hand 
then treated without or with PDGF (20 ng/ml) for 48 h. After PDGF treatment, cells 
were exposed to 50 I-IM HNE in HBSS for 30 min and then replaced with 10% 
FBS/DMEM. Cells were then harvested or left in the incubator for a further 3.5 h. 
Cells were lysed using lysis buffer and 25 I-Ig used for Western blot to quantify 
protein-HNE adducts using an anti-protein HNE antibody [133]. 
LDH activity assay: VSMCs were serum starved for 24h and then treated without 
or with PDGF (20 ng/ml) for 48 h. After PDGF treatment, cells were exposed to 50 
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IJM HNE in HBSS for 30 min and then replaced with 10% FBS/DMEM media. After 
16 h, the medium was collected and Iysates were prepared by scraping cells in 100 
pi of PBS containing 0.1 % Triton X-100. LDH activity was measured 
spectrophotometrically for 4 min at 37°C by monitoring decrease in NADH 
absorbance at 340 nm. Cytotoxicity was then estimated by dividing the change in 
absorbance of the medium by the values for combined LDH activity in the medium 
and the lysate as follows; cytotoxicity = [(Abs34o media * dilution factor) I (Abs34o 
Media * dilution factor) + (Abs lysate * dilution factor)] * 100. The values were then 
normalized relative to the control, which represented 100% cell viability [163]. 
Adeno-viral gene fransfecfion: VSMCs were serum starved for 24 h and then 
infected with replication-deficient adenoviruses carrying either GFP (AdGFP) or 
GFP fused LC3 (AdGFP-LC3). Adenoviruses were used at a multiplicity of infection 
(MOl) of 100 and GFP expression was used to ascertain transfection efficiency. 
AdGFP or AdGFP-LC3 transfected cells were then stimulated with PDGF at the 
indicated times. Before imaging, cells were incubated with Hoechst stain for 
nuclear visualization. 
Immunofluorescence confocal imaging: VSMCs were washed with PBS and 
then fixed in ice-cold (-20 DC) methanol for 5 min. The cells were then incubated 
for 30 min at room temperature (RT) in a blocking solution (5% BSA in PBS) 
followed by incubation for 1 h with a 1 :500 dilution of anti-a-sm-actin primary 
antibody at room temperature. A 1: 1 ODD-diluted solution of goat anti-mouse IgG 
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Alexa555 secondary antibody was used for incubation after treatment with the 
primary antibody. After three washes with PBS, the cells were counterstained with 
DAPI for 10 min at RT. The cells were then mounted on glass slides using the 
mounting medium and cover slips were added. a-SMA staining was visualized 
using a NIKON A 1 confocal microscope. Cells plated on glass-bottom dishes were 
transfected with adenoviruses as described above. After loading with each dye, the 
cells were placed in phenol red-free DMEM supplemented with 25 mmol/L HEPES 
(pH 7.4). The cells were illuminated (488- and 568-nm lines of a krypton/argon 
laser), and images were acquired. 
Transmission electron microscopy: VSMCs were grown on cover slips (Ladd 
Research, Williston, VT, U.S.A.), serum-starved for 24 h, and then treated with 
PDGF (20 ng/ml) for 48 h. Control cells were left untreated. After treatment, cells 
were washed with PBS and fixed with 3% glutaraldehyde in 0.1 M sodium 
cacodylate buffer (pH 7.4) for 2 h at room temperature (25°C). The cells were 
then post-fixed with 1% osmium tetroxide, sectioned and embedded in LX112 
plastic. Ultrathin sections were stained with uranyl acetate and lead citrate, and 
electron micrographs were taken using a PhilipsCM10 transmission electron 
microscope operating at 60 kV (x1 000- 72000 magnification) [133]. 
Statistical analysis: Data are mean ± SEM. Multiple groups were compared using 
one-way ANOVA, followed by Bonferroni post-tests. Unpaired Student's t test was 
used for direct comparisons. A p value <0.05 was considered significant. 
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Results 
Platelet derived growth factor induces phenotype switching in VSMCs: To 
examine the mechanisms regulating the phenotypic transition of VSMCs, we first 
measured changes in molecular markers of contractile and synthetic VSMC 
phenotypes. For this, VSMCs were deprived of serum for 24 h to induce cell cycle 
arrest. The cells were then incubated with vehicle or PDGF-BB (20 ng/ml) for 24 
and 48 h. Relative mRNA and protein abundance was measured by RT-PCR and 
Western blotting, respectively. As shown in Fig. 1A, PDGF treatment for 24 h 
resulted in a - 50% decreases in the mRNA levels of a-sm-actin and calponin and 
a robust upregulation of osteopontin (12-fold) and vimentin (2-fold). After 48 h, the 
levels of a-SMA protein were decreased by 25%, calponin abundance was 
decreased by 75%, and osteopontin protein was elevated 2-fold (Figure 1 Band 
1 C). Immunofluorescence imaging of a-SMA filaments showed marked 
disorganization in PDGF-treated cells compared with control cells 48 h after PDGF 
treatment (Figure 1 D). These results confirm previous findings [36, 50, 162] 
showing that PDGF promotes phenotypic transition of VSMCs. 
PDGF induces autophagy in VSMCs: The relatively rapid loss of contractile 
proteins suggested to us that proteolytic mechanisms may function to remove the 
contractile apparatus to aid in the transition from the contractile to the synthetic 
phenotype. Indeed, previous studies have shown that proteasome and calpain 
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inhibitors affect VSMC phenotype [164-166]; however, these studies showed that 
proteasome inhibition counter intuitively decreases markers of the contractile 
phenotype [165] resulting in reduced cell contractility[166]. Therefore, we 
hypothesized that autophagy may be important for the removal of contractile 
proteins and protein complexes. To test this hypothesis, we first assessed the 
effects of PDGF on autophagy in VSMCs by examining LC3-11 formation-an 
indicator of autophagy [167-168]. As shown in Fig. 2A-C, PDGF stimulation 
caused a time-dependent increase in LC3-11 formation. A significant increase in 
LC3-11 was observed 12 h after PDGF stimulation and maximal increases in LC3-11 
were obtained 48 h after PDGF treatment, suggesting that stimulation with PDGF 
increases autophagy. 
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Figure 1. PDGF induces a contractile-to-synthetic phenotype switch in 
VSMCs. Indices of vascular smooth muscle cell phenotype: A) Quantitative 
real-time PCR following PDGF-BB (20 ng/ml) stimulation for 24 h. Calponin, 
a-sm-actin and MHC II are markers of the contractile phenotype, osteopontin 
and vimentin are associated with a synthetic phenotype. *p<0.05 vs control, 
n=3 per group. B) Western analysis of contractile and synthetic proteins after 
PDGF stimulation: VSMCs were serum-starved for 24 h and then stimulated 
with PDGF for 48 hand 0.5-2 IJg protein was used for immunoblot analysis. 
C) Quantification of immunoblots from panel B (n=3 per group, *p<0.05 vs 
control). D) Confocal images of a-sm-actin (red) distribution in VSMCs 
treated without and with PDGF (20 ng/ml) for 48 h. Blue staining indicates 
nuclear staining with DAPI (Scale bar = 20 IJm). 
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Because the formation of LC3-11 is transient and the protein is rapidly degraded in 
the lysosome, an increase in LC3-11 could also paradoxically indicate a decrease in 
autophagy. Hence, to determine total LC3-11 formation, we inhibited its lysosomal 
degradation by treating cells with bafilomycin A 1, which inhibits vacuolar-type H+-
ATPase [168-169]. As shown in Fig. 2D-F, treatment of PDGF-stimulated cells with 
bafilomycin led to a greater increase in LC3-11 abundance than was observed in 
untreated cells, indicating a net increase in LC3-11 formation and upregulation of 
autophagic machinery in PDGF-treated cells (Fig. 2D-F). These effects appear to 
be specific to PDGF because treatment with fibroblast growth factor 1 (FGF-1), a 
known VSMC mitogen [170], did not affect the abundance of contractile proteins or 
increase LC3-11 formation, despite increasing cell proliferation to levels similar to 
that of PDGF (Fig. 2G-J). To obtain further evidence for the induction of 
autophagy by PDGF, we transduced VSMCs with a GFP-LC3 adenovirus and 
assessed the formation of punctate LC3, which is indicative of its autophagosomal 
localization [168]. As shown in Fig. 3A-B, there was a 2-fold increase in 
fluorescent puncta in PDGF-treated cells, and this was further increased by 
bafilomycin A 1 treatment. 
PDGF induces ultrastructural changes and extensive vacuolization in 
VSMCs: Although LC3-11 formation is a validated marker of autophagy, changes in 
the ultrastructure showing the formation of autophagosomes is considered the 
"gold-standard" for documenting autophagy. Hence, to examine ultrastructural 
changes, VSMCs were treated with PDGF for 48 h and then visualized by 
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transmission electron microscopy. Transmission electron micrographs of these 
cells showed that treatment with PDGF (20 ng/ml) for 48 h caused a -3 fold 
increase in autophagosomes (indicated with red arrows, Fig. 3D, E) when 
compared with untreated cells (Fig. 3C). In addition, PDGF treatment resulted in 
extensive vacuolization and consistent formation of a singular, large phagosome 
per cell, which may serve as a designated compartment for the digestion of 
intracellular materials. Collectively, these structural changes are in concordance 
with our immunological and fluorescence-imaging data and suggest that PDGF is a 
robust inducer of the autophagic program. 
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Figure 2. PDGF-BB induces autophagy in VSMCs. Quantification of LC3 
abundance and localization to puncta: A) Immunoblot analysis of LC3. After 24 h of 
serum deprivation, VSMCs were stimulated with PDGF for 24 h and abundance of 
LC3 was detected by Western blotting; B, C) Quantification of LC3 from panel A. 
*p<0.05 vs control group, n = 3 per group; D) Measurements of autophagic flux: 
Bafilomycin A 1 (2 !-1M) was added to control or PDGF-stimulated cells 4 h prior to 
harvest. Accumulation of LC3-11 was measured by Western blotting; E, F) 
Quantification of LC3 from panel D. *p<0.05 vs. the indicated group, n=3 per 
group. (n=3 per group, #p<0.05 vs baf or vs PDGF+baf, *p<0.05 vs Ctrl); and G-J) 
Effects of FGF-1 on proliferation, contractile protein abundance, and autophagic 
flux in VSMCs: panel J, comparison of VSMC proliferation when treated with FGF-
1 (25 ng/ml) and PDGF-BB (25 ng/ml) for the indicated time. Cells were counted at 
the end of the treatment period using a hemocytometer. Panel H, representative 
western blots of contractile proteins in cells treated with FGF-1 (0-50 ng/ml); Panel 
I, representative western blot of autophagic flux in untreated and FGF-1-treated 
cells. Note that bafilomycin (2 !-1M) was added 4 h prior to harvesting cells. Panel 
J, densitometry measurements of LC3 from panel H. *p<0.05 vs. control group, n = 
3 per group. 
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PDGF-induced autophagy is required for phenotype switching: To examine 
whether autophagy plays a role in VSMC phenotype switching, we pretreated 
VSMCs with the pharmacological inhibitor of autophagy, 3-methyladenine (3-
MA)[171], prior to stimulating the cells with PDGF. As shown in Fig. 4A and B, 3-
MA decreased GFP-LC3 puncta formation by 50%. This inhibition of autophagy 
was associated with partial stabilization of the contractile markers calponin and a-
SMA (Fig. 4A-D) and inhibition of smooth muscle cell proliferation (Fig. 4E). 
Because of potential, off-target effects of 3-MA [172-174] and the relatively high 
concentrations of the compound needed to inhibit the autophagic machinery, we 
tested whether spautin-1, a more specific inhibitor of autophagy, would affect 
VSMC phenotype. Spautin-1 has been recently shown to prevent autophagy by 
inhibiting the deubiquitinases USP10 and USP13, which leads to beclin 1 
degradation (Fig. 5A) [175]. Pretreatment of VSMCs with spautin-1 (10 IJM) 
prevented PDGF-induced disorganization of actin filaments (Fig. 5B). Western blot 
analysis demonstrated that inhibition of autophagy with spautin-1 prevented 
increases in LC3-11 and losses of calponin and a-SMA after PDGF exposure (Fig. 
5C-F). Spautin treatment also prevented VSMC hyperproliferation (Fig. 5G). 
To determine if the proteasome plays a role in regulating VSMC phenotype 
switching, we treated cells with the proteasome inhibitor epoxomicin [176] prior to 
PDGF treatment and examined contractile protein expression. Although 
epoxomicin treatment inhibited proteasomal activity, as evidence by the increased 
abundance of ubiquitinated proteins (Fig. 6A, B), the loss of contractile proteins 
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due to POGF treatment remained largely unaffected (Fig. 6C-E). Collectively, 
these results suggest that autophagy, and not proteasomal activity, is required for 
phenotypic changes in POGF-stimulated VSMCs. 
Synthetic VSMCs are resistant to aldehyde-induced cell death: Lesions in 
atherosclerotic and restenotic vessels are characterized by increased amounts of 
proteins modified by lipid peroxidation products such as 4-hydroxy-trans-2-nonenal 
(4-HNE) [177-178]. Because previous findings suggest that autophagy prevents 
toxicity due to 4-HNE [133], we hypothesized that synthetic VSMCs having higher 
autophagic flux might be protected from 4-HNE-induced cell death. This could be 
important because synthetic VSMCs are the abundant phenotype found in vascular 
lesions; hence, their survival may be impacted by their ability to handle oxidative 
insults. Indeed, as shown in Fig. 7 A, cell viability of synthetic VSMCs challenged 
with HNE was significantly enhanced compared with HNE-challenged contractile 
VSMCs (p<O.05). Consistent with the role of autophagy in clearing oxidatively 
damaged proteins [133, 179], synthetic VSMCs resisted accumulation of protein-
HNE adducts due to exogenous HNE exposure (Fig. 7B and C). Inhibiting 
autophagy with spautin-1 promoted accumulation of HNE-damaged proteins (Fig. 
70 and E). These results suggest that POGF-induced autophagy may be important 
for promoting the survival of VSMCs found in diseased vessels. 
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Figure 3. PDGF-BB increases autophagosome formation and promotes 
extensive vacuolization. Microscopic evaluation of autophagy and VSMC 
ultrastructure: A) Representative confocal images of VSMCs transfected with Ad-
GFP (i and ii) or Ad-GFP-LC3 (iii, iv, v, and iv) treated without or with PDGF and/or 
bafilomycin; B) Quantification of puncta in panel B (> 20 cells counted per field in 
each group, *p<0.01 vs. the indicated groups; C-E) Representative transmission 
electron micrographs of cells treated with vehicle (panel C) or PDGF (panel D) for 
48 h. E) Magnified image of boxed area in panel B. Double membrane-bound 
structures identified as autophagosomes in panels D and E are indicated by the 
red arrows. N=nucleus, M=mitochondria, V=vacuoles. Magnification = x7100 F) 
Quantification of autophagosomes in images from control and PDGF treatment 



























! CTRL PDGF 
Discussion 
The present study demonstrates autophagy as a novel mechanism regulating 
VSMC phenotype. We found that PDGF, which promotes the development of the 
synthetic VSMC phenotype, is a robust inducer of autophagy and that 
pharmacological inhibition by two structurally-unrelated inhibitors of autophagy 
blocked the degradation of calponin and a-sm-actin and prevented 
hyperproliferation and the transition to the synthetic phenotype. We also found 
that the synthetic phenotype was more resistant to the electrophilic stress 
commonly encountered in diseased vessels, and this was associated with an 
increased ability to remove proteins damaged or modified by electrophiles. These 
findings uncover PDGF-mediated autophagy as an important regulator of VSMC 
phenotype. 
Previous studies have identified numerous factors that regulate phenotype 
plasticity in VSMCs. For example, contractile agonists, reactive oxygen species 
and extracellular matrix components have been shown to regulate the expression 
of contractile genes [53-54, 180-184]. Conversely, growth factors such as PDGF 
and oxidized phospholipids are known to favor the synthetic phenotype [50, 61, 66, 
185]. Several studies have elucidated molecular mechanisms governing the switch 
to the synthetic phenotype. The signaling pathways known to trigger the synthetic 
phenotype culminate in the displacement of myocardin, a coactivator of serum 
response factor, from the consensus CArG box upstream of smooth muscle cell 
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marker genes [186]. PDGF is known to act through transcription factors such as 
KLF4 and Elk-1 as well as microRNAs (such as miR221 and miR222) leading to 
the displacement of myocardin and downregulation of VSMC contractile genes [92, 
124, 187 -188]. Hence, most studies to date examined transcriptional and 
translational changes regulating phenotypic transition; few, however, have 
explored post-transcriptional and -translational mechanisms. 
We posited that one limiting event to transition to the synthetic phenotype would be 
removal of the contractile apparatus. Degradation of contractile proteins would 
likely involve the proteasome, autophagy, or both. Interestingly, the proteasome 
has been shown to playa role in VSMC hyperplasia but not phenotype switching 
[130, 189]; and paradoxically, inhibitors of the proteasome decrease markers of the 
contractile phenotype [165] resulting in reduced cell contractility [166]. In our 
studies, we found that inhibition of the proteasome with epoxomicin had little effect 
on contractile protein abundance, suggesting to us that autophagy could be the 
major proteolytic device employed by the cell to remove contractile proteins. 
We found that PDGF induced a robust form of autophagy characterized by 
increased LC3-11 abundance, augmented autophagic flux, and the formation of 
autophagosomes and vacuoles. The induction of autophagy was specific to 
PDGF: the mitogen FGF, while increasing proliferation to a similar extent as 
PDGF, did not induce autophagy. While factors such as TNF-a and osteopontin 
have been shown to promote autophagy in VSMCs [109, 190], there are 
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surprisingly few reports of induction of autophagy by growth factors. In fibroblasts 
and cancer cells, connective tissue growth factor (CTGF) has been shown to 
activate autophagy and regulate proliferation [191], and transforming growth factor-
~ (TGF-~) activates autophagy in hepatocellular carcinoma cells [192]. In these 
cases, the induction of autophagy is usually associated with diminished 
proliferation; however, we found that autophagy may be important for PDGF-
mediated hyperproliferation, as inhibition of autophagy with 3-MA or spautin-1 
prevented cellular proliferation induced by PDGF. We hypothesize that this may 
be due either to stabilization of contractile proteins, which might structurally hinder 
cell division, or to decreased generation of metabolic building blocks, e.g., amino 
acids, which would be a natural consequence of enhanced autophagic activity and 
could be used to supply energy requirements for increased proliferation. 
It remains unclear why rapamycin, which is an inhibitor of mTOR and activator of 
autophagy, promotes the contractile phenotype in VSMCs [83, 193] while PDGF-
mediated autophagy induces the synthetic phenotype. It is likely that the form of 
autophagy induced by PDGF is uniquely poised to degrade contractile proteins and 
is tailored to regulate the phenotype switch. 
In addition to contractile proteins, autophagy has been shown to be important in 
preventing accumulation of damaged or aggregated proteins [133, 179, 194]. We 
found that the increase in autophagic flux in PDGF-treated VSMCs was sufficient 
to decrease cell death and the abundance of protein-HNE adducts after an 
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aldehyde challenge, suggesting that synthetic VSMCs may be better able to 
tolerate the high levels of oxidant stress occurring in vascular lesions. This may be 
an important feature of synthetic cells, as it may regulate the survival of VSMCs in 
the fibrous cap, which, at least in part, is responsible for maintaining plaque 
stability [195]. Interestingly, the form of autophagy induced by PDGF appears to be 
functionally different from what has been described to occur with other stimuli. For 
example, TNF-a and IGF-1 were shown to increase autophagy in VSMCs, yet 
promote an autophagic form of cell death [190]. That PDGF promotes autophagy, 
cell survival, and increases the formation of extracellular matrix therefore suggests 
that it safeguards plaque-resident VSMCs against oxidative injury while potentially 
increasing the stability of lipid-laden atherosclerotic plaques. 
Although the non-specific effects of pharmacological inhibitors cannot be rigorously 
ruled out, our observation that two structurally different inhibitors that target 
different components of the autophagic machinery were effective at stabilizing 
calponin and a-SMA support the view that autophagy is required for PDGF-
induced phenotype conversion. Nevertheless, spautin was more robust in 
stabilizing the contractile VSMC phenotype, and it completely prevented the 
hyperproliferation of VSMCs after PDGF exposure. The inhibition of autophagy 
with spautin did not affect PDGF signaling through Akt and Erk, further suggesting 
that inhibition of phenotype switching was due to stabilization of the contractile 
apparatus (Figure 8). These results suggest that spautin might be a useful 
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therapeutic agent for preventing abnormal proliferation of smooth muscle cells in 
vascular injury or restenosis. 
In summary, the present study identifies a new mechanism by which autophagy is 
activated and shows that autophagy is critical for attaining a synthetic VSMC 
phenotype and for increasing resistance to oxidative stress. Our observations also 
suggest that therapies targeting autophagy might be useful in preventing aberrant 
smooth muscle cell growth, but that such interventions may have deleterious 
effects on synthetic smooth muscle cell survival under conditions of oxidative 
stress. Future studies are required to identify the detailed molecular mechanism(s) 
by which PDGF activates the autophagic program and to test how modulating 
PDGF-mediated autophagy affects the progression of vascular disease. 
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Figure 4. Inhibition of autophagy prevents PDGF-induced phenotype 
switching. Measurements of autophagy and contractile phenotype in cells treated 
with autophagy inhibitors: A) Representative confocal images of VSMCs treated 
with PDGF in the absence or presence of 3-MA (10 mM). B) Quantification of 
fluorescent puncta from panel A. *p<0.03, n=10 per group. C) Western analysis of 
contractile protein expression. VSMCs were serum-starved for 24 h and then 
stimulated with PDGF (20 ng/ml) for 48 hours. 3-MA (10 mM) was added 30 min 
prior to PDGF stimulation. D-E) Quantification of immunoblots represented in panel 
C. F) Cell proliferation in VSMCs: VSMCs were treated with vehicle or PDGF in the 
absence or presence of 3-MA. After 48 h, the cells were trypsinized and counted 
using a hemocytometer. *p<0.05 vs. PDGF only and #p<0.05 vs non-PDGF-
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Figure 5. Spautin 1, an inhibitor of autophagy, prevents PDGF-induced 
phenotype switching. A) Mechanism of action of spautin 1: Spautin 1 promotes 
the degradation of beclin 1 through inhibition of USP10 and USP13 
deubiquitinases; B) Representative confocal images VSMCs treated without or 
with PDGF in the absence or presence of spautin 1 (10 !-1M). Scale bar = 10 !-1m. C) 
Representative Western blots of LC3 and contractile proteins. D-F) Quantification 
of immunoblots from panel C. G) Cell proliferation in VSMCs: VSMCs were treated 
with vehicle or PDGF in the absence or presence of spautin-1. After 48 h, the cells 
were trypsinized and counted using a hemocytometer. *p<O.05 vs. CTRL; #p<O.05 
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Figure 6. Inhibition of the proteasomal pathway does not inhibit PDGF-
induced contractile protein degradation. Immunoblot analysis of ubiquitinated 
proteins and contractile proteins: A) Accumulation of ubiquitinated proteins after 
epoxomicin (100 nM) treatment; B) Quantification of A (n=3 per group, *p<0.05 vs 
control). C-E) Effects of epoxomicin on calponin and a-sm-actin degradation. C} 
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Figure 7. Synthetic VSMCs are resistant to HNE-induced toxicity. A) Cell 
viability in HNE-treated cells: VSMCs were treated with vehicle or PDGF for 48 h 
and then exposed to HNE (50 !-1M) for 30 min in HBSS. The HNE-containing 
medium was removed and replaced with growth medium, and cell viability was 
assessed by LDH assay 16 h later. *p<0.05 vs. HNE, &p<0.05 vs CTRL, n=3 per 
group. 8, C) Protein-HNE adduct formation in contractile (control) and synthetic 
(PDGF-treated) cells: The cells were treated with HNE (50 !-1M) for 30 min in 
HBSS. The medium was then replaced with growth medium and the cells were 
harvested after 3.5 h for examination of HNE adducts. Representative protein-
HNE blots are shown in panel B and quantification is shown in panel C. *p<0.005 
vs HNE, n=3 per treatment group. 0) Representative immunoblots of protein-HNE 
adducts in contractile and synthetic VSMCs treated without (left panel) or with 
spautin-1 (right panel). E) Quantification of groups shown in panel D. All 
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Figure 8. Spautin 1 does not interfere with PDGF-induced Akt or Erk1/2 
signaling. A) Western blot analysis of Akt and Erk1/2 phosphorylation status: 
VSMCs were pretreated with spautin-1 for 30 min before PDGF stimulation at the 





























~ ~ 1.0x107 
-'£ 









o 1030120 0 1030120 PDGF (Mins) 




o 1030120 0 1030 120 PDGF (Mins) 
I +Spautin 1 I 
62 
CHAPTER III 
REGULATION OF VASCULAR SMOOTH MUSCLE CELL 
PROLIFERATION AND PHENOTYPE SWITCHING BY O-GlcNAc 
Introduction 
Glucose metabolism in VSMCs occurs via four major pathways: the glycolytic, 
the polyol, the hexosamine biosynthetic, and the pentose phosphate pathways. 
These pathways have been shown to regulate VSMC hyperplasia and function. 
For example, inhibition of aldose reductase, the rate-limiting enzyme in the polyol 
pathway, prevents VSMC proliferation induced by the cytokine TNF-a [196]; 
increased flux into the hexosamine biosynthetic pathway (HBP) has been shown 
to inhibit VSMC proliferation and reduce neointima formation after balloon injury 
[197]; increased glycolytic flux promotes PDGF-induced VSMC hyperplasia [198]; 
and, glucose-6-dehydrogenase (G6PD), the rate-limiting enzyme in the pentose 
phosphate pathway, has been shown to regulate VSMC contractility [199]. Thus, 
glucose metabolism is an important aspect of vascular complications involving 
the VSMC. Despite such findings, vascular proliferative diseases such as 
atherosclerosis continue to be major causes of death [200]. Therefore further 
understanding of glucose metabolism in the VSMC is needed to expose new 
avenues for clinical intervention. 
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VSMC hyperproliferation is mediated by growth factors and environmental cues. 
Platelet derived growth factor BB (PDGF-BB or PDGF) is the most potent inducer 
of VSMC proliferation and it is released from platelets, macrophages, and 
endothelial cells during vessel injury [36]. PDGF stimulation of VSMCs causes 
increased secretion of cytokines, particularly osteopontin, a pro-proliferative 
cytokine which is important for VSMC migration and extracellular matrix 
formation during atherogenesis and restenosis [103]. The levels of osteopontin 
expression are regulated by transcription factors which are under the influence of 
cellular glucose levels [201]. This suggests that regulating glucose metabolism 
(or cellular glucose concentrations) could be important in regulating VSMC 
osteopontin expression and VSMC proliferation. In particular, the mechanisms by 
which glucose metabolism regulate osteopontin expression are unclear and how 
accessory pathways, such as the HBP, affect OPN expression and VSMC 
phenotype are understudied. 
The hexosamine biosynthetic pathway (HBP) utilizes about 2-5% of glucose in 
mammalian cells [202], and this pathway has been implicated in VSMC 
neotintimal formation during vascular remodeling [203]. The enzyme, L-
glutamine-D-fructose 6-phosphate amidotransferase (GFAT) is the regulatory 
enzyme mediating glucose flux into the HBP [204]. GFAT converts fructose-6-
phosphate to glucosamine-6-phosphate which, through a series of reactions is 
subsequently converted to uridine diphosphate N-acetylglucosamine (UDP-
GlcNAc). UDP-GlcNAc is then used as a donor for the formation of O-linked-N-
acetylglucosamine (O-GlcNAc) modified proteins as well as other proteoglycans, 
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glycosamino glycans, and glycolipids [205]. O-GlcNAc modification regulates 
several biological processes such as apoptosis, signal transduction, transcription, 
translation, nuclear transport and protein degradation [206-213]. O-GlcNAcylation 
is also important in diseases such as cancer, diabetes and Alzheimer's disease 
[214-217]. To date, two key enzymes which perform kinase-like and 
phosphatase-like activities with respect to protein O-GlcNAc modification have 
been described: O-GlcNAc transferase (OGT) catalyses the transfer of the 
GlcNAc (I3-N-acetylglucosamine) moiety from UDP-GlcNAc to conserved 
serine/threonine residues of protein via an O-linkage [218]. Proteins which have 
been O-GlcNAc modified are converted back to their unmodified form through the 
action of O-GlcNAcase which removes the GlcNAc moiety to form UDP-GlcNAc 
[219]. Flux into the HBP controls levels of O-GlcNAcylated proteins, and OGT is 
very sensitive to levels of cellular UDP-GlcNAc [220]. In 1998, Nerlich et al [221] 
found an increase in GFAT expression under hyperglycemic conditions thereby 
suggesting a role of the HBP in diabetic vascular complications. Akimoto et al 
[222] later showed that high glucose caused elevated OGT expression leading to 
alteration of protein O-GlcNAc patterns. These studies suggest that the increase 
in VSMC hyperplasia observed under hyperglycemia is attributable to increased 
in glucose flux into the HBP. However, several studies have shown the contrary, 
for example, Slawson et al [223] showed that increasing levels of protein 0-
GlcNAc modification using pharmacological inhibitors such as PUGNAc (which 
inhibits O-GlcNAcase) or through adenoviral gene over expression of OGT led to 
altered expression of cyclins and defects in mitotic progression. Subsequently, 
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Xing et al [203] showed that increasing protein O-GlcNAc by glucosamine or 
PUGNAc treatment inhibited neointima formation after balloon injury of the rat 
carotid artery. This inhibition, Xing and colleagues suggest, was due to inhibition 
of cytokine expression after injury. However, the direct role of the HBP and 0-
GlcNAc protein modification on VSMC phenotype has not been assessed. 
Therefore, studies addressing the effects of glucose metabolic pathways such as 
glycolysis and the HBP on phenotype switching and hyperproliferation are 
needed. 
In this study, we determined the effects of the GAPDH inhibitor, koningic acid 
(KA), and the O-GlcNAcase inhibitor, thiamet-g on PDGF-induced VSMC 
proliferation. These inhibitors have been demonstrated to be specific to their 
respective targets at low concentrations while producing minimal or no side 
effects [224-225]. Both KA and thiamet-g prevented PDGF-induced VSMC 
proliferation. KA inhibited glucose flux to glycolysis and inhibited osteopontin 
expression. These effects of KA resulted in inhibition of PDGF-induced 
proliferation. KA treatment led to a small but significant increase in levels of 
protein O-GlcNAc formation thereby suggesting an antiproliferative role of the 
HBP. Indeed, Thiamet-g treatment, which caused increased protein O-GlcNAc 
formation, inhibited PDGF-induced osteopontin expression, and stalled the cells 
in the S-phase of the cell cycle. Expression of cell cycle proteins cyclin D1 and 
PCNA were inhibited in the presence of Thiamet-g. These findings reveal the 
importance of the glycolytic and the HBP pathways with respect to PDGF-
induced VSMC proliferation and reveal two new inhibitors of VSMC proliferation 
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that could potentially be developed for the treatment of vascular diseases such 
as atherosclerosis and restenosis. 
Experimental procedures 
Materials: Antibodies against a-smooth muscle cell-actin (a-SMA), calponin and 
a-tubulin were purchased from Sigma-Aldrich (St. louis, MO, USA). Antibodies 
against GAPDH, p-AkUAkt and p-Erk1/2/Erk1/2 were purchased from Cell 
Signaling (Danvers, MA, USA). Antibodies against osteopontin, cyclin D1 and 
PCNA were purchased from Santa Cruz biotechnology (Santa Cruz, CA, USA). 
Antibody against protein O-GlcNAc was obtained from Covance (Princeton, NJ, 
USA). Recombinant rat PDGF was obtained from R&D Biosystems (Minneapolis, 
MN, USA). HRP conjugated rabbit and mouse IgG secondary antibodies were 
obtained from Cell Signaling Technologies (Danvers, MA, USA). All primers used 
for real time PCR were designed using the primer express software from Applied 
Biosystems (Carlsbad, CA, USA) and then ordered from Integrated DNA 
Technologies (Coralville, lA, USA). Electrophoresis supplies were purchased 
from Bio-Rad (Hercules, CA, USA). ECl ® reagents were purchased from GE 
Healthcare (Pittsburgh, PA, USA). MTT reagent was obtained from Sigma Aldrich 
(St. louis, MO, USA). Koningic acid was obtained from COSMO BIO CO lTD 
(Carlsbad, CA, USA). Thiamet-G was obtained from Cayman Chemical (Ann 
Arbor, MI, USA). The Cyquant proliferation assay kit was obtained from 
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Invitrogen Life Technologies (Grand Island, NY, USA). Propidium Iodide was 
purchased from eBioscince (San Diego, CA, USA). 
Cell culture: Rat aortic smooth muscle cells (VSMCs) were isolated from the 
aortas of 6-week-old male Sprague-Dawley rats and grown in DMEM (Dulbecco's 
modified Eagle's medium; Life Technologies-Invitrogen) supplemented with 10% 
(v/v) FBS (fetal bovine serum; Atlanta Biologicals, Atlanta, GA, USA) and 0.1 % 
streptomycin/penicillin. To ensure maintenance of the contractile phenotype, only 
cells between passages 2-7 were used. Cells were maintained in a humidified 
atmosphere of air and 5% CO2 at 37°C. At -70% confluency, VSMCs were serum-
starved in DMEM containing 0.1 % FBS for 24 h. After desired treatments, cells 
were rinsed twice with phosphate-buffered saline and then lysed in a protein lysis 
buffer containing 25 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.1 % SDS, 1 % NP-
40, and 1X protease and phosphatase inhibitors. The Lowry DC assay (Biorad, 
City, St., USA) was used for measuring protein concentration of crude cell extracts. 
Messenger RNA isolation and real-time peR: Messenger RNA was isolated 
from RASMCs using TRIZOL reagent (Invitrogen) and the concentration was 
determined by measuring absorbance at 260nm using a Nanodrop 
spectrophotometer (Thermo scientific). A 20 1-11 reverse transcription reaction 
mixture containing 1 I-Ig mRNA, 10 units AMV reverse transcriptase, 0.4 I-IM poly T 
primer (dT18), 0.2 mM dNTPs, and 20 units RNasin (Promega) was subjected to 
complimentary DNA (cDNA) synthesis in a thermal cycler (BioRad). Two 
microliters of cDNA was then used for amplification of the gene of interest by real 
time PCR using SYBR green (VWR, Radnor, PA, USA). 
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Western blotting: Approximately 0.5-25 I-Ig of crude cell protein was applied to 
each lane of a 10.5-14% Bis-Tris-HCI gel and electroblotted onto a PVOF 
membrane. The membrane was then incubated overnight at 4°C using appropriate 
dilutions of primary antibodies. PVOF membranes were then incubated at room 
temperature with horseradish peroxidase-conjugated secondary antibodies. 
Immunoreactive bands were detected using a typhoon scanner (SA Biosciences, 
Valencia, CA, USA) after exposure to ECl detection reagent. Bands intensity was 
quantified by using the Totallab Tl120 software. 
For protein O-GlcNAc Western blots: VSMCs were treated with PUGNAc or 
thiamet-g, inhibitors of O-GlcNAcase, or vehicle (0.1 % ethanol) for overnight and 
then treated with POGF for 48 h. Total cell lysate was prepared as described 
above. After transfer of proteins onto PVOF, membrane was immediately put in 
methanol for 1 min and then allowed to dry at RT for 2 h. After drying, membrane 
was incubated with 1: 1 000 dilution of anti-protein O-GlcNAc antibody (diluted in 
PBS-casein; cat no. 161-0783, Bio-Rad, Hercules, CA, USA) for overnight. 
Membrane was then washed 3x10 mins each and then incubated with appropriate 
secondary antibody (diluted in PBS-casein) for 1 h at RT. After second incubation, 
membrane was imaged using the Typhoon scanner. 
Measurement of cellular energetics using the XF24 extracellular flux 
analyser: Cellular energetics was measured in intact VSMCs using a Seahorse 
Bioscience XF24 extracellular flux analyser. Approximately 40,000 cells were 
seeded in wells of a 24-well XF plate. Cells were then serum starved in 0.1 %FBS 
OM EM for 24h. After serum starvation the media was replaced with phenol red 
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free DMEM containing 1 mM pyruvate, 5 mM glucose and 3.97mM Glutamax-I. 
After equilibration in phenol red free DMEM, PDGF was then injected into cells 
and their extracellular acidification rates (ECARs) measured. Oligomycin was 
later injected to obtain the maximal glycolytic capacity of the cells. Koningic acid 
(KA) was added to inhibit glycolysis. Data obtained were normalized to the 
amount of protein present in the well of the microplate. For normalization, cells 
were lysed in the 24-well XF plates using 20 pI/well of protein lysis buffer. Protein 
concentration was then measured using the Lowry's method. 
Cell cycle studies with propidium iodide: VSMCs were harvested after 3 min 
trypSin incubation, washed with phosphate buffered saline (PBS) and cold 70% 
ethanol added to the cells. VSMCs were then fixed by incubating for 1 hour at 
4°C. After fixing, cells were sedimented at 500 x g for 5 mins and the supernatant 
discarded. Cells were then washed again with PBS and 3001-11 RNase buffer 
containing 51-11 propidium iodide added after all residual PBS has been discarded. 
Cells were then mixed and incubated at room temperature for 45 mins after 
which they were analyzed using a C6 Accuri flow cytometer. 
Cell viability assays: VSMCs were serum starved for 24h and then treated 
without or with PDGF (20 ng/ml) for 48 h. After PDGF treatment, cells were 
exposed to 50 I-IM HNE in HBSS for 30 min and then replaced with 10% 
FBS/DMEM media. After 16 h, the medium was collected and Iysates were 
prepared by scraping cells in 100 pi of PBS containing 0.1 % Triton X-100. LDH 
activity was measured spectrophotometrically for 4 min at 37°C by monitoring 
decrease in NADH absorbance at 340 nm. Cytotoxicity was then estimated by 
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dividing the change in absorbance of the medium by the values for combined 
LDH activity in the medium and the lysate as follows; cytotoxicity = [(Abs34o 
media * dilution factor) / (Abs34o Media * dilution factor) + (Abs lysate * dilution 
factor)] * 100. The values were then normalized relative to the control, which 
represented 100% cell viability. 
For cytotoxicity assays, after desired treatment, cells were incubated in a solution 
of 0.2 mg/ml MTT reagent for 2-4h at 37°C in an incubator containing 5% CO2. 
After incubation, MTT reagent was then aspirated and the purple crystals at the 
bottom of the plate dissolved in DMSO. Absorbance at 540 nm was then 
measured using a microplate reader. 
Statistical analysis: Data are mean ± SEM. Multiple groups were compared using 
one-way ANOVA, followed by Bonferroni post-tests. Unpaired Student's t-test was 
used for direct comparisons. A p-value <0.05 was considered significant. 
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Results 
PDGF induces expression of osteopontin in cultured VSMCs: To determine 
the effects of PDGF on glucose metabolism in isolated VSMCs, we first 
measured changes in proliferation and osteopontin expression on VSMCs 
isolated from rat aortas. For this, VSMCs were serum starved for 24 h in 0.1 % 
FBS and then stimulated with PDGF (20ng/ml) for 24 h. Consistent with previous 
findings, PDGF induced about a 2.5-fold increase in osteopontin protein 
abundance, increased proliferation by 2-fold as measured by counting cell 
number or measuring DNA content (Figure 9A and B). The increase in cell 
proliferation was accompanied with 1.7- and 2.3-fold increases in the expression 
of cell cycle regulatory proteins such as cyclin 01 and PCNA, respectively 
(Figure 9C and D). 
PDGF increases glycolytic flux in VSMCs: To determine the effects of PDGF 
on glycolytic flux, we serum starved VSMCs for 24 h and then stimulated serum 
starved cells with different concentrations of PDGF. As shown in Figure 10, 
PDGF at a concentration of 25ng/ml increased basal and maximal glycolytic flux 
with an insignificant increase in the glycolytic reserve capacity. Koningic acid 
completely inhibited glycolytic flux in VSMCs. 
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Figure 9. PDGF-BB induces VSMC proliferation and expression of 
osteopontin. A and B) Measurement of cell proliferation after PDGF stimulation. 
Cell proliferation measured by counting cell numbers (A) and by measurement of 
cellular DNA content using the cyquant fluorescent dye (B), n=6, *p<O.01 vs. 
control. C and D) Expression of cell cycle proteins and osteopontin after PDGF 
stimulation. (C) Western blot of cyclin D1, PCNA and osteopontin after PDGF 
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PDGF-induced os teop on tin expression is dependent on glycolysis: To 
determine whether the increase in glycolytic flux caused by PDGF stimulation is 
important for proliferation and expression of the key synthetic gene osteopontin, 
we stimulated VSMCs with PDGF in the presence of koningic acid. As shown in 
Figures 11A-C, koningic acid inhibited PDGF-induced VSMC proliferation. PDGF 
stimulation of VSMCs caused significant increases in mRNA (14-fold increase) 
and protein levels (2.5-fold increase) of osteopontin and these were inhibited by 
koningic acid (Figures 11D-F). These findings are all consistent with published 
data implicating the role of osteopontin in VSMC proliferation [201] and are novel 
because it is the first time that it is being directly shown that glycolytic flux is 
important in PDGF induced VSMC osteopontin expression. 
Koningic acid treatment increases protein-O-GlcNAc formation: We treated 
VSMCs with different concentrations of KA and monitored protein O-GlcNAc 
formation. We found that protein O-GlcNAc formation was increased (Figure 12). 
This suggested to us that increased protein O-GlcNAc formation might be a 
unique mechanism regulating OPN expression and VSMC proliferation. 
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Figure 10. PDGF-BB induces increase in glycolytic flux. A) Extracellular flux 
analysis after PDGF stimulation. B) Quantification of basal and maximal ECARs 
after PDGF stimulation (n=5, *p<O.05 vs. control). 
76 
Figure 10 
A -+- Ong/ml 
3 
+ 1ng/ml 
-e- Sng/ml oligolTIlcin 
-v- 10ng/ml koningic acid 
-+- 2Sng/ml / c 2 "m ..... 
0 ..... 
Q. 









~ Basal - Maximal c - * "Q) 20 ...... -.- Reserve 0 
~ 
(J) 0.. 15 a:::C) 
~ :::l Uc 




0 5 10 15 20 25 30 
POGF(ng/ni) 
77 
Protein O-GlcNAc regulates VSMC proliferation and os teop on tin 
expression: Because changes in protein O-GlcNAc were observed after POGF 
and KA stimulation, we further studied the role of increased O-GlcNAc formation 
in POGF-induced VSMC proliferation and osteopontin expression. Increasing flux 
to the HBP results in increased activity of the enzyme O-GlcNAc transferase 
(OGT) [226] that attaches GlcNAc moieties to protein molecules [220]. 0-
GlcNAcase removes these GlcNAc moieties in a reverse reaction [219]. The 
global levels of protein O-GlcNAcylated can thus be increased by either, 
increasing flux into the HBP (increasing OGT activity) or by inhibiting the enzyme 
O-GlcNAcase. We therefore treated VSMCs with Thiamet-g to determine the 
effects of increasing protein O-GlcNAc formation on VSMC proliferation and OPN 
gene expression. At non-toxic doses, Thiamet-g caused a concentration 
dependent increase in protein O-GlcNAc formation (Figure 13A-0). This increase 
in protein O-GlcNAcylation resulted in inhibition of proliferation induced by POGF 
(Figure 14A) and expression of cell cycle proteins PCNA and cyclin 01 (Figures 
14B-0). 
To verify whether the anti-proliferative effect of Thiamet-g was due to impaired 
upstream POGF signaling, we measured the phosphorylation status of Akt and 
Erk1/2 proteins which are activated upon POGF stimulation and are known to 
mediate POGF mitogenic effects in VSMCs [50]. As shown in Figure 15, 
Thiamet-g caused no observable difference between POGF stimulated and 
unstimulated groups. This further confirmed that increasing protein O-GlcNAc 
formation inhibits proliferation by inhibiting expression of cell cycle proteins and 
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not by interrupting upstream POGF signaling. We further measured expression of 
the synthetic cytokine, OPN, in the presence of Thiamet-g. As shown in Figure 
16, osteopontin mRNA expression was inhibited in the presence of thiamet-g. 
This result is consistent with the effect of KA on POGF-induced VSMC 
proliferation and OPN expression and suggests that the anti-proliferative effect of 
Thiamet-g may be mediated in part by inhibition of OPN expression. 
Because the expression of cell cycle proteins, PCNA and cyclin 01 were 
inhibited by thiamet-g, we went further to determine if Thiamet-g had any effect 
on cell cycle progression. Using propidium iodide staining, we found that in the 
presence of Thiamet-g, POGF stimulated cells showed significantly slower 
progression into the Sand G2/M phases of the cell cycle (Figure 17). 
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Figure 11. PDGF-induced glycolytic flux is required for proliferation and 
osteopontin expression. A-C) Effects of koningic acid on POGF-induced 
proliferation. Serum starved VSMCs were treated for 24 with POGF (20ng/ml) in 
the absence or presence of koningic acid (0.5IJg/ml). Cell proliferation was 
measured using MTT assay (A) or by counting cell numbers (8). C) LOH assay 
after koningic acid treatment. Concentration dependent effects of koningic acid 
on cytotoxicity. *p<0.05 vs control (0 IJg/ml koningic acid). D) Quantitative real 
time PCR. Osteopontin mRNA expression in the presence of koningic acid ± 
POGF. Serum starved VSMCs were stimulated with POGF ± koningic acid for 
24h and gene and protein abundance measured by real time PCR (0) and 
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Figure 12. Inhibiting glycolytic flux increases HBP flux. Immunoblot analysis 
of protein O-GlcNAc formation after koningic acid treatment. A) Increase protein 
O-GlcNAcylation after koningic acid treatment. B) Quantification of A (n=3, 
*p<O.05 vs. 0 IJg/ml). 
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Discussion 
The present study shows a role for glycolysis in PDGF-induced osteopontin 
expression and PDGF-induced VSMC hyperplasia. This study also demonstrates 
the importance of protein O-GlcNAc modification in regulating PDGF-induced 
hyperproliferation. Using the inhibitor of glycolysis, koningic acid, we found that 
after PDGF treatment, the expression of the proinflammatory cytokine 
osteopontin was inhibited. Interestingly, inhibiting glucose flux into glycolysis by 
KA treatment led to increased protein O-GlcNAc formation. Independently 
increasing the levels of protein O-GlcNAc formation by inhibiting the enzyme 0-
GlcNAcase also led to the inhibition of osteopontin expression and expression of 
cell cycle proteins PCNA and cyclin D1 causing the delay of cell cycle 
progression. These findings uncover a new role of glycolysis and O-GlcNAc 
protein modification in regulating the expression of the synthetic cytokine 
osteopontin and in regulating VSMC proliferation. 
Regulation of osteopontin expression is known to be under the influence of 
different transcription factors. For example, CREB, NFAT, AP-1, USF, SP1, Myc 
and Oct-1 are known to regulate osteopontin expression after PDGF stimulation 
and osteopontin expression is necessary for some PDGF-induced changes in the 
VSMCs [114, 201, 227-229]. Some of these transcription factors are under the 
control of cellular glucose levels and glucose uptake, and glycolysis is known to 
increase VSMC hyperplasia induced by PDGF [198, 201]. However, the role of 
glycolysis in OPN expression has remained unclear. 
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Other pathways of glucose metabolism such as the polyol pathway are known 
regulators of VSMC hyperplasia. In fact, administering sorbinil, an aldose 
reductase inhibitor, prevented VSMC hyperplasia in culture and after balloon 
injury of the carotid artery [230-231] indicating an important role of this pathway 
in VSMC hyperproliferation. Also, although controversial, the HBP has been 
implicated in VSMC hyperplasia and neointima [203, 222-223]. Here, we present 
data that supports an anti-proliferative role of increasing protein O-GlcNAc. Our 
studies highlight new findings implicating the role of glycolysis and protein 0-
GlcNAc in OPN expression. We showed that increasing protein O-GlcNAc 
formation has an inhibitory effect on VSMC hyperplasia and this inhibitory effect 
could be mediated, in addition to inhibiting cell cycle protein expression, through 
decreased OPN expression. 
The fact that protein O-GlcNAc formation was increased in the presence of KA 
suggests that glucose metabolism can be regulated and redirected into a 
different pathway upon perturbation in one pathway. The increased protein 0-
GlcNAc formed after koningic acid treatment suggests that the antiproliferative 
effects of inhibiting glycolysis (i.e., by KA treatment) could be mediated in part by 
protein O-GlcNAc formation. These are important observations although the 
molecular mechanism(s) leading to these observed effects have not been 
rigorously tested. However, it is possible that the changes in glucose metabolism 
caused by PDGF regulates glucose-controlled transcription factors such as 
upstream stimulatory factor (USF) leading to inhibition of osteopontin expression 
and VSMC proliferation. We noticed that progression of the cell cycle through 
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the S-phase was significantly delayed in the presence of thiamet-g thereby 
suggesting that mechanisms regulating S-phase transition could have been 
inhibited. The inhibitors, koningic acid and thiamet-g did not alter PDGF-induced 
autophagy (observed in chapter II) or PDGF-induced degradation of contractile 
proteins thereby suggesting that the process of cellular degradation during 
phenotype switching might simultaneously be occurring via a pathway 
independent of osteopontin expression and proliferation. 
In summary, the study presented in this section identifies possible roles of 
glucose metabolic pathways in regulating VSMC proliferation and osteopontin 
expression. This study highlights the importance of glucose metabolism in 
attaining the fully synthetic phenotype characterized by, in addition to decreased 
contractile protein expression, increased osteopontin expression and increased 
proliferation. Our study suggests possible therapies that could be developed and 
used (in drug eluting stents) to curb VSMC hyperproliferation. Future studies are 
needed to delineate the complete mechanism by which these inhibitors produce 
their effects. 
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Figure 13. Thiamet-g increases protein O-GlcNAcylation in VSMCs. 
Immunoblot analysis of protein O-GlcNAc formation after thiamet-g treatment. A) 
Serum starved VSMCs were treated with Thiamet-g at the indicated 
concentrations. B) Densitometric quantification of A (n=3, *p<O.03 vs OIJM). C 
and 0) Cytotoxicity due to Thiamet-g treatment. Cell toxicity was measured using 
the MTT assay and the LDH assay (*p<O.01 vs control). Thapsigargin was used 
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Figure 14. Increased protein O-GlcNAcylation inhibits PDGF-induced VSMC 
proliferation. Cell proliferation assay. (A) Serum starved VSMCs were treated 
with POGF (20ng/ml) ± Thiamet-g and proliferation measured by counting cell 
numbers (n=6, *p<O.03 vs. POGF). (8) Expression of cell cycle proteins. 
Immunoblot analysis of PCNA and cyclin 01 abundance after POGF ± treatment. 
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Figure 15. Thiamet-g does not inhibit PDGF signaling. (A) Immunoblot 
analysis of Akt and Erk1/2 phosphorylation after PDGF± Thiamet-g treatment. (8 
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Figure 16. Increased protein O-GlcNAcylation inhibits PDGF-induced 
osteopontin expression. Quantitative real time PCR. Serum starved VSMCs 
were treated for 24h with PDGF (20ng/ml) ± Thiamet-g (n=3, #p<O.01 vs control 
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Figure 17. Thiamet-g causes delayed cell cycle progression. Cell cycle 
analysis with propidium iodide. VSMCs serum starved for 24h and then 
stimulated with PDGF or PDGF + Thiamet-g for the indicated time points. Cell 
cycle progression was monitored using a C6 Accuri flow cytometer (n=3, 
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MITOCHONDRIA FISSION REGULATES METABOLISM AND VSMC 
PROLIFERATION 
Introduction 
Rapidly proliferating cells require an increase in energy production and elevated 
formation of metabolic intermediates. These demands can be achieved by 
increasing the metabolism of major substrates such as glucose, glutamine or 
fatty acids. In synthetic VSMCs which are not only rapidly dividing, but are 
migratory and secreting ECM, the requirements for cellular energy are even 
higher. To meet with these demands, synthetic VSMCs could increase their 
overall metabolic flux or switch to oxidizing metabolic substrates that provide 
more energy. Thus, metabolizing more efficient substrates, such as fatty acids 
could be an efficient means of satisfying cellular needs during excessive 
proliferation and migration. 
Mitochondria are the cellular hubs of metabolism and have the capacity of both 
changing their substrate preference as well as their morphology. Previously, 
mitochondria were regarded as static organelles with the principal function of 
producing ATP needed for cellular respiration. However, with the discovery of 
different proteins that regulate mitochondrial morphology, these organelles are 
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now known to be dynamic and capable of changing their morphology to regulate 
different cellular processes, such as calcium handling [232] and apoptosis [233]. 
During cell proliferation, mitochondria form giant networks which are known to be 
associated with increased ATP formation [234]. This network formation typically 
occurs during the G1 to S transition of cell cycle in which the cellular glycolytic 
rates are low. Thus, mitochondria network formation maximizes energy 
production during these times of increased synthetic activity. 
A number of mitochondria related proteins are now known to regulate 
mitochondria morphology. For example dynamin related protein 1 (DRP1) and 
human mitochondria fission protein 1 (hFis1) promote mitochondria fission [235-
236]. Conversely, mitofusins 1 and 2 (Mfn1 and 2) and optic atrophy 1 (Opa1) 
promote mitochondrial fusion. Changes in mitochondrial morphology 
(mitochondrial fragmentation) occurs in apoptotic cell death [237-238]. Recent 
studies have shown that mitochondrial morphology is instrumental in the process 
of mitophagy whereby long tubulated mitochondria are spared from incorporation 
into the autophagosome [239]. Mitochondrial morphology in diseased conditions 
such as ischemia reperfusion injury, diabetes, cytosolic calcium overload, heart 
failure and dilated cardiomyopathy has also been studied [240-243]. However, 
the role of mitochondria in the VSMC during phenotype conversion has not been 
given great attention with only a few recent studies suggesting a role of Mfn2, 
Drp1 and mitochondria morphology in VSMC hyperproliferation under diseased 
conditions [244-245]. 
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In this study, we examined the effects of PDGF on mitochondrial morphology and 
metabolism. We found that synthetic VSMCs utilize increase fatty acid oxidation 
(FAO) in response to PDGF which was preceded by mitochondria fragmentation. 
Mitochondria fragmentation induced by PDGF was accompanied by decreased 
expression of the pro mitochondria fusion gene mitofusin 2 thereby suggesting a 
mitofusin 2-mediated mechanism. Mitochondria fragmentation was necessary for 
increased FAO and increased proliferation because mdivi-1, an inhibitor of 
mitochondria fragmentation, prevented PDGF-induced FAO and proliferation. 
This increase in FAO was not due to an increase in mitochondria content 
because the total mitochondria abundance did not change in the synthetic cells. 
Collectively, these data demonstrate that substrate switching to FAO is important 
in generating energy needed for the synthetic VSMC and identifies mitochondria 





Reagents: Antibodies against VDAC, COX IV and ATP synthase 13 were 
obtained from Novus Biologicals (Littleton, CO, USA). The Mito ID red dye and 
Hoechst stain were obtained from Enzo life sciences (Farmingdale, NY, USA). 
Etomoxir, FCCP, antamycin A and rotenone were obtained from Sigma Aldrich 
(St. Louis, MO, USA). Rabbit polyclonal antibody against rat Mfn2 was obtained 
from Abcam. Recombinant FGF-1 was obtained from eBiosciences (San Diego, 
CA, USA). Antibodies against a-smooth muscle cell-actin (a-SMA), calponin and 
a-tubulin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rabbit 
polyclonal antibody against LC3 was purchased from Cell Signaling 
Technologies (Danvers, MA, USA). Propidium iodide was purchased from 
eBiosciences (San Diego, CA, USA). 
Cell culture: Rat aortic smooth muscle cells (RASMCs) were isolated from the 
aortas of 6 weeks old male Sprague-Dawley rats and grown in DMEM 
(Dulbecco's modified Eagle's medium; Life Technologies-Invitrogen) 
supplemented with 10% (v/v) FBS (foetal bovine serum) and 0.1 % 
streptomycin/penicillin. Cells used in experiments were from between passages 
2-7 maintained in a humidified atmosphere of air and 5% CO2 at 37 cC. At about 
70% confluency, RASMCs were serum starved in DMEM containing 0.1 % FBS 
for 24 hours. After desired treatments, cells were rinsed twice with phosphate 
buffered saline and then lysed in a protein lysis buffer containing 25 mM HEPES, 
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1 mM EOTA, 1 mM EGTA, 0.1% SOS, 1% NP-40, 1x protease and phosphatase 
inhibitors. Lowry's assay was used for measuring protein concentration of crude 
cell extracts. 
Western blotting: For Western blotting, between 0.5-25 I-1g of crude cell protein 
was applied to each lane of a 10.5-14% Bis-Tris gel and electroblotted onto a 
PVOF membrane. The membrane was then incubated overnight at 4°C using 
appropriate dilutions of primary antibodies. The PVOF membranes were 
incubated at room temperature with horseradish peroxidase-conjugated 
secondary antibodies. Immunoreactive bands were detected with enhanced 
chemiluminescent detection reagent (GE Healthcare). 
Confocal Imaging: Cells plated on glass-bottom dishes were serum starved for 
24h in 0.1 % FBS OMEM. Cells were then stimulated with POGF and desired co-
treatments for the desired times. For visualization, mitochondria were stained 
using the mito 10 kit from Enzo life sciences (Farmingdale, NY, USA) following 
the specified protocol. Mito 10 and Hoechst stains were diluted in phenol red-free 
OMEM supplemented with 25 mmol/L HEPES, pH 7.4) and then added to cells 
for 10 mins. For imaging, cells were illuminated with desired laser and images 
acquired using a 60x objective lens covered with a thin layer of oil. 
Measurement of cellular energetics using the XF24 extracellular flux 
analyser: Cellular energetics was measured in intact VSMCs using a Seahorse 
Bioscience XF24 extracellular flux analyzer. Fifty thousand cells were seeded in 
12-wells of a 24-well XF plate (Control group), while twenty five thousand cells 
were seeded in the remaining 12 wells (POGF treated group). Cells were then 
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serum starved in 0.1 % FBS DMEM for 24h and then stimulated with 20 ng/ml 
PDGF in the same media for 48 h. After PDGF stimulation, media was replaced 
with DMEM containing 100 !-1M BSA-palmitate, 1 mM pyruvate, 5 mM D-glucose, 
and 100 !-1M L-carnitine. After equilibration in the media, the cells were exposed 
to etomoxir and OCR was measured. Data obtained were normalized to the 
amount of protein present in the well of the microplate. For normalization, cells 
were lysed in the 24-well XF plates using 20 pi/well of protein lysis buffer. Protein 
concentration was then measured using the Lowry's method. 
Cell proliferation assays and measurement of cell viability: Vascular smooth 
muscle cells were serum starved for 24h in order to synchronize cells in the GO 
phase. After serum starvation, cells were treated for the required duration as 
indicated. After treatment, cells were rinse twice with PBS and then trypsinized 
with a 0.25% trypsin solution for about 3 minutes at 37°C. Cells were then re-
suspended in DMEM containing 10% FBS and cell numbers were determined 
using a C6 Accuri flow cytometer. For viability assays, after desired treatment, 
cells were incubated in a solution of 0.2 mg/ml MTT reagent for 2-4 h at 37°C in 
an incubator containing 5% C02. After incubation, MTT reagent was then 
aspirated and the purple crystals at the bottom of the plate dissolved in DMSO. 
Absorbance at 540 nm was then measured using a microplate reader. 
Cell cycle studies with propidium iodide: VSMCs were harvested after 3 min 
trypsin incubation, washed with phosphate buffered saline (PBS) and cold 70% 
ethanol added to the cells. VSMCs were then kept at 4°C for 1 hour to fix cells. 
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After fixing, cells were sedimented at 500 x g for 5 mins and the supernatant 
discarded. Cells were then washed again with PBS and 300 IJI RNase buffer 
containing 5 IJI propidium iodide added after all residual PBS has been 
discarded. Cells were then mixed and incubated at room temperature for 45 min 
after which they were analyzed using a C6 Accuri flow cytometer. 
Statistical analysis: Data are mean ± SEM. Experimental groups were compared 
using one-way ANOVA, followed by Bonferroni post-tests. Unpaired Student's t-
test was used for direct comparisons. A p-value <0.05 was considered significant. 
Results 
Synthetic VSMCs show increased fatty acid oxidation and mitochondria 
fragmentation: To examine energetic changes that occur in synthetic VSMCs, 
we measured fatty acid oxidation (FAO) after PDGF stimulation. We serum 
starved VSMCs and then converted one group to the synthetic phenotype by 
PDGF treatment for 48 h, while the other group was left untreated. Oxygen 
consumption was then measured in media containing L-carnitine and only BSA-
palmitate and glucose as available substrates. To interrogate the contributions of 
FAO and glucose oxidation to the overall oxidative phosphorylation, we added 
etomoxir into the media and then monitored oxygen consumption rates (OCRs). 
Etomoxir is an inhibitor of carnitine palmitoyl transferase 1, an enzyme needed 
for conjugating and translocating long chain fatty acids from the cytoplasm to the 
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mitochondria where they are committed to p-oxidation [246]. Addition of etomoxir 
should therefore cause a drop in OCR and this drop in OCR will be due to 
inhibition of p-oxidation or FAD (see scheme 5). As shown in Figure 18, 
etomoxir injection decreased in OCR to a greater extent in PDGF treated cells 
compared with control cells, thereby indicating an increase in FAD in synthetic 
cells. This increase in FAD could not be due to differences in the amount of cells 
nor changes in mitochondria abundance because the results were normalized to 
protein expression per well and because a Western blot analysis of mitochondria 
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Figure 18. PDGF treatment increases fatty acid oxidation in VSMCs. Oxygen 
consumption measurements in contractile and synthetic VSMCs A) 
Representative extracellular flux measurements. VSMCs were serum starved for 
24 h and then left untreated or converted to the synthetic phenotype by PDGF 
stimulation for 48 h (OCR drop after etomoxir injection is fatty acid linked). OCRs 
were normalized to total proteins. B and C) Quantification of A. (Total oxidative 
phosphorylation activity = (point 7 - point 8). Percent oxygen consumption due to 
FAO = (point 3 - point 4)/ (point 7 - point 8)*100. Percent due to GO = (100 -




















CTRL + ETO 





> ;::; g 30 
~~ 
u. "6. 20 




















Figure 19. Increased FAO in synthetic VSMCs is not due to increased 
mitochondria abundance. Total mitochondria abundance was not changed 
upon conversion to the synthetic phenotype. A) Representative Western blot. 
VSMCs were starved for 24 h and then treated without or with PDGF for 48 h. B-
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It was recently reported that changes in mitochondrial morphology and network 
formation play important roles in energy production and proliferation of VSMCs 
[247-248]. We therefore went further to determine whether the observed change 
in substrate utilization was accompanied with changes in mitochondria 
morphology. As shown in Figure 20A, synthetic VSMCs had mainly small 
rounded or fragmented mitochondria (globular) as opposed to contractile cells 
whose mitochondria were mainly filamentous and network forming. The 
expression of mitofusin 2, a pro-mitochondria fusion gene, was down regulated in 
synthetic cells thereby suggesting a mitofusin 2-dependent mechanism of 
mitochondrial fragmentation (Figure 20C and D). Interestingly, this change in 
mitochondria shape and substrate utilization was specific to cells stimulated with 
PDGF because FGF-1 neither increased FAO nor did it cause mitochondrial 
fragmentation (Figure 21). 
Mitochondria fragmentation causes increased FAD in synthetic VSMCs: To 
determine whether changes in mitochondria morphology influenced substrate 
usage in synthetic cells, we stimulated VSMCs with PDGF in the presence of the 
mitochondria fission inhibitor (DRP1 inhibitor), mdivi1 [249] and measured 
changes in OCR after etomoxir injection. As shown in Figures 22A and B, mdivi1 
inhibited the fragmentation caused by a switch to the synthetic phenotype. This 
inhibition also prevented the switch to FAO observed upon conversion to the 
synthetic phenotype (Figures 22C and D). The inhibition of mitochondria 
fragmentation caused a complete blockage of PDGF-induced proliferation by 
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decreasing the expression of cell cycle proteins cyclin D1 and PCNA and stalling 
cells in the s-phase of the cell cycle (Figure 23). 
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Figure 20. PDGF induces mitochondria fragmentation in VSMCs. 
Mitochondria morphology in contractile and synthetic VSMCs. A) Representative 
live cell confocal images of untreated or 48 hour PDGF treated cells. B) 
Mitochondrial morphologies. Mitochondria lengths were measured using the NIS 
Elements software and scored as follow: Mitochondrial morphology was scored 
as follows: Globular, mainly small and round « 2 IJm in diameter); intermediate, 
between 2-4 IJm in length; and filamentous, long and higher interconnectivity (> 4 
IJm in length). The percentage of cells with indicated mitochondrial morphologies 
was determined as a percentage of the total number of stained cells counted 
(~150 cells per experiment), n = 4 independent experiments, blue = hoechst, red 
= mito ID red. (Scale bar: 10 IJm). C) PDGF-induced mitochondria fragmentation 
is associated with loss of mitofuscin 2. Representative Western blot analysis of 
mitofusin 2 expression after PDGF time course stimulation. D) Quantification of 
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Figure 21. FGF-1 does not induce mitochondria fragmentation/fatty acid 
oxidation. Mitochondria morphology and FAO in VSMCs exposed to FGF-1. A) 
Representative extracellular flux measurements. VSMCs were serum starved for 
24h and then stimulated with FGF-1 for 48 h. B and C) Quantification of A. Total 
oxidative phosphorylation activity = (point 7 - point 8). % oxygen consumption 
due to FAO = (point 3 - point 4)/ (point 7 - point 8)*100. % due to GO = (100 -
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To verify if mitochondrial fragmentation acts upstream of FAD, we stimulated 
cells with PDGF in the presence of etomoxir and then measured changes in 
mitochondrial morphology. As shown in Figure 24, etomoxir inhibited PDGF-
induced proliferation but had no effect on mitochondria fragmentation, suggesting 
that mitochondria fragmentation precedes increases in FAD and proliferation. 
Dur results suggest that VSMCs in the synthetic phenotype increase FAD and 
this increase in FAD is regulated by mitochondria morphology because only the 
globular (fragmented) mitochondria phenotype was associated with increased 
FAD. 
PDGF-induced contractile protein degradation during phenotype switching 
is NOT dependent on mitochondria fragmentation and FAO: We previously 
determined that conversion to the synthetic phenotype required induction of 
autophagy, which is needed for the degradation of contractile proteins such as 
calponin and a-SM actin (Figure 5). Since inhibition of mitochondria 
fragmentation inhibited PDGF-induced proliferation and because increased 
proliferation is associated with the synthetic phenotype, we wanted to verify if 
mitochondrial fragmentation and increased FAD were required for PDGF-induced 
contractile protein degradation leading to the emergence of the synthetic 
phenotype. As shown in Figure 25, inhibition of PDGF-induced fragmentation did 
not affect degradation of contractile proteins suggesting that contractile protein 
degradation is not dependent on changes in mitochondrial morphology and 
increased FAD. We went further to determine whether inhibiting PDGF-induced 
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autophagy (or contractile protein degradation) would affect mitochondrial 
fragmentation. Also, Spautin1, an inhibitor of autophagy, did not inhibit PDGF 
induced fragmentation. These data suggest that contractile protein degradation 
and mitochondria fragmentation occur via separate pathways. The relative 
contributions of these pathways lead to the emergence of a fully dedifferentiated 
VSMC characterized by decreased expression of smooth muscle cell contractile 
proteins, increased proliferation and other synthetic characteristics such as 
increased migration and ECM synthesis (see Scheme 6). 
Discussion 
Our present study shows that mitochondrial morphology is important for 
regulating substrate usage and VSMC proliferation in the synthetic phenotype. 
We demonstrated that conversion of VSMCs into the synthetic phenotype is 
accompanied by increased FAO which is preceded by mitochondrial 
fragmentation. This change in mitochondria morphology appears to be required 
for increasing FAO and proliferation, as mdivi1 inhibited both mitochondrial 
fragmentation and proliferation. We also found that although the change in 
substrate metabolism was required for increased proliferation, it did not have any 
effect on PDGF-induced contractile protein degradation. These findings uncover 
mitochondrial fragmentation as one of many extensive cellular changes occurring 
during conversion into the synthetic phenotype. 
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Beta oxidation of long chain fatty acids occurs in the mitochondria and yields two 
times more ATP per gram when compared with glucose or amino acids [250-
251]. Thus, under conditions of excessive energy demand, cells are more likely 
benefit from FAO. Since long chain FAs cannot freely diffuse through the 
mitochondrial inner membrane, a transport system is required. This transport 
system comprises a group of enzymes known as carnitine palmitoyl transferases 
(CPT) [252]. CPT1, the rate limiting enzyme of the CPT system [252], catalyses 
the transfer of an acyl group from coenzyme A on an activated FA to carnitine to 
form palmitoylcarnitine. Palmitoylcarnitine is then shuttled across the inner 
mitochondria membrane where it is converted back into palmitoyl-CoA. Palmitoyl-
CoA can be broken down to acetyl-CoA which enters the TCA cycle to yield ATP 
and the reducing equivalents NADH and FADH2 [253]. We found that etomoxir, 
an inhibitor of CPT1, inhibited PDGF-induced VSMC proliferation but not 
mitochondria fragmentation. 
We proposed that changes in mitochondria morphology induced by PDGF 
regulate substrate utilization. Changes in substrate metabolism could lead to 
increased glycolysis (resulting in increased flux of pyruvate into mitochondria) or 
could lead to increased FA utilization or both. Interestingly, we found that in 
addition to increased glycolysis after PDGF stimulation of VSMCs, FAO was also 
increased. These combined increases in glycolysis and FAO may be important 
for supporting energy requirements and cellular changes in the fully synthetic 
phenotype. 
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Previous studies in other cell types show that promotion of mitochondrial fission 
by knock down of Mfn2 leads to reduced mitochondrial membrane potential, less 
oxidative phosphorylation and increased dependency on glycolysis, possibly 
mediated through reduced expression and activity of different subunits of the 
electron transport chain [254]. In the case of POGF-induced mitochondrial 
fragmentation, we found that the overall oxidative phosphorylation of both 
contractile and synthetic cells remained the same and there were no changes in 
expression of the subunits in the electron transport chain (Figure 19). 
Mitochondria fission was found to be important in POGF-induced proliferation 
through a mechanism involving regulation of expression of cell cycle proteins 
such as PCNA and cyclin 01. In fact, in the presence of Mdivi1, the expression of 
PCNA and cyclin 01 were inhibited and cells became stalled in the S-phase. 
However, it remains to be clearly elucidated whether the effects of Mdivi1 on 
proliferation are linked to its mitochondria-fission-inhibitory effect or due to a 
different effect. It is however important to note that the effects on proliferation 
observed with Mdivi1 concur previous findings showing that promotion of 
mitochondria fusion through overexpression of Mfn2 promote inhibition of VSMC 
proliferation [244]. 
Collectively, these studies provide novel insights into the role of mitochondria in 
POGF-induced proliferation. Mitochondria morphology is a determinant of 
substrate usage but not of protein degradation during phenotype switching. 
Identification of the role of mitochondria in VSMC opens new avenues for 
therapeutic management of atherosclerosis and restenosis. 
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Figure 22. PDGF-induced mitochondrial fragmentation results in increased 
FAO. Inhibition of mitochondria fission inhibits PDGF-induced fragmentation and 
FAD. A) Representative confocal images of serum starved VSMCs treated 
without or with PDGF ± Mdivi-1. Morphology is shifted towards the filamentous in 
the presence of Mdivi1. B) Quantification of A. Fil = filamentous, Glo = Globular 
and Int = Intermediate. (~150 cells counted per experiment, experiment was 
repeated at least two times). C) Representative extracellular flux measurements. 
VSMCs were serum starved for 24h and then left untreated or converted to the 
synthetic phenotype by PDGF treatment for 48h ± Mdivi1. D) Quantification of C 





























-<>- CTRL FC\ 
-e- MDIVI1 
....... PDGF ...... PDGF+MDIVI1 
±ETO 
~ 
































+ + mdivi-1 
+ + PDGF 
Figure 23. Inhibition of mitochondrial fragmentation decreases PDGF-
induced proliferation. A) Cell proliferation after PDGF ± mdivi1 treatment. 
VSMCs were serum starved for 24 h and then treated for 24 h (n = 5 per 
treatment group, *p<O.03 vs control, &p<O.01 vs PDGF). B) Inhibition of cell cycle 
protein expression by mdivi1. VSMCs were serum starved for 24h and then 
stimulated with PDGF for the indicated times in the absence or presence of 
mdivi1. C and D) Quantification of B (n = 3 per treatment group, *p<O.05 vs 
untreated). E) Cell cycle analysis using propidium iodide. Mdivi1 stalls cells in the 
S-phase of cell cycle. Cells in upper panel were stimulated with PDGF for the 
indicated times while cells in the lower panel were stimulated with PDGF but in 
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Figure 24. FAO is required for PDGF-induced proliferation. Etomoxir inhibits 
PDGF-induced proliferation. A) Concentration dependent effect of etomoxir on 
VSMC proliferation. Cell proliferation was measured by counting cell numbers 
using the Accuri C6 flow cytometer (n=6, *p<O.05 vs untreated). B) Cell viability 
by MTT assay. VSMCs after exposure to different concentrations of etomoxir 
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Figure 25. Mitochondria fragmentation and FAO are not prerequisites for 
POGF-induced contractile protein degradation. Mdivi1 does not inhibit PDGF-
induced autophagy and contractile protein degradation. A) Representative 
immunoblot after PDGF ± mdivi1 treatment. Cells were serum starved for 24h 
before treatment. 8-0) Quantification of A (n=3, *P<O.05, **p<O.01 vs untreated). 
E) FAO is not required for PDGF-induced autophagy and contractile protein 
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Our studies were aimed at developing a better understanding of how metabolism 
regulates VSMC phenotype. For this, we examined processes relating to protein 
degradation and studied metabolic changes occurring during and after VSMC 
phenotype transition. We proposed that in addition to inducing other cellular 
processes needed for the conversion to the synthetic phenotype, PDGF induces 
autophagy as a means to degrade unwanted cellular components, making way 
for the emergence of a fully synthetic phenotype. We also proposed that PDGF 
stimulation regulates cellular metabolism to increase energy production which 
supports proliferation and synthetic VSMC activity. 
In the first set of experiments we wanted to determine which protein degradation 
pathways are primarily involved during phenotype switching. We examined the 
proteasomal and the autophagic pathways - the predominant pathways of 
cellular degradation in mammalian cells. We found that inhibition of the 
proteasomal pathway had limited effects on 
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PDGF-induced degradation of calponin and sm-a-actin. This suggested to us that 
the autophagic pathway of protein degradation could be involved during 
phenotypic conversion. 
The conversion to the synthetic phenotype requires rapid cellular changes and 
degradation of contractile proteins, which would be thought to require proteolytic 
pathways such as autophagy or the proteasome. In mammalian cells, autophagy 
is known to be the major pathway through which cellular contents are degraded 
during growth and transformation. We therefore examined the role of autophagy 
during phenotype transition. In chapter II, we presented data showing that PDGF 
promotes autophagy in VSMCs. The induction of autophagy by a mitogen is 
atypical, because other growth factors (e.g., insulin) have been shown to inhibit, 
rather than activate, autophagy. PDGF-induced autophagy appears to be 
important in phenotype switching because inhibition of autophagy with different 
structural inhibitors led to stabilization of calponin and sm-a-actin. This appears 
to be specific to PDGF because other mitogens such as FGF-1 neither induced 
autophagy nor promoted phenotypic switching. 
Interestingly, PDGF-induced autophagy was protective against HNE-induced 
toxicity. This is consistent with multiple studies showing that autophagy is a 
survival response activated during starvation and under conditions of oxidative 
stress. Because HNE is a constituent of atherosclerotic lesions known to form 
protein-HNE adducts and to cause cytotoxicity, the heightened autophagy in 
synthetic cells could render these cells stress resistant hence enhancing plaque 
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stability during atherogenesis. Our findings therefore support the notion that 
(mitogen-mediated) autophagic induction in VSMCs could be protective, 
therefore exposing new therapeutic avenues. However, in the context of 
atherosclerosis, the manipulation of autophagy for therapeutic success should be 
approached with caution because induction of autophagy can be maladaptive as 
well. For example, excessive induction of autophagy might eventually trigger 
autophagy-induced cell death or type 2 cell death, resulting in increased plaque 
destabilization [255]. 
The induction of autophagy during phenotypic conversion may also be 
advantageous to the rapidly proliferating synthetic cell. Since autophagy 
degrades cellular components to their constituent amino acids, these could be 
used as building blocks for different and new macromolecules prevalent in the 
synthetic cells. The importance of autophagy in this regard could be seen from 
the findings that inhibiting autophagy decreased VSMC proliferation, a key 
feature of the synthetic phenotype. Our findings therefore suggest a role of 
autophagy in VSMC proliferation. This novel role could also be exploited for 
therapeutic advantage in vasculo-proliferative complications such as restenosis 
[27]. 
In chapter III, we found that an increase in glycolytic flux after PDGF treatment 
does not only increase mitochondrial activity [145], but it is also required for the 
expression of the synthetic gene OPN. OPN is a cytokine secreted by synthetic 
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VSMCs and it is known to promote plaque formation by promoting VSMC 
migration into intima. Our findings therefore suggest a possible link between 
glycolysis and vascular lesions caused by VSMC hyperproliferation. Our findings 
also confirm previous findings implicating the role of glucose-regulated 
transcription factors in OPN expression. 
POGF-induced OPN expression was also partly regulated by O-GlcNAc 
formation. Increasing O-GlcNAc formation via Thiamet-g treatment inhibited 
POGF-induced OPN expression. This finding supports previous findings 
suggesting an inhibitory role of increased HBP flux (or O-GlcNAc) in VSMC 
hyperproliferation. However, in hyperglycemic conditions such diabetes, 
increased flux into the HBP has been thought to contribute to VSMC 
hyperproliferation and has been associated with an increased incidence of CVO. 
Our results therefore suggest the contrary because increased levels of O-GlcNAc 
(an end product of increased HBP flux) had inhibitory effects on VSMCs. 
However, it is worth noting that increased flux to the HBP does not necessarily 
imply an increase in (protein) O-GlcNAc formation. Also, the diabetic condition is 
not only characterized by increased glucose flux into the HBP, but also by other 
conditions such as increased levels of circulating free fatty acids. 
The increased O-GlcNAc formation observed after Thiamet-g treatment was 
associated with delay in cell cycle progression and decrease expression of cell 
cycle proteins cyclin 01 and PCNA. Thiamet-g-treated cells were stalled 
between the G1 and S-phases of cell cycle. Since O-GlcNAc modification is a 
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posttranslational modification, the inhibitory effects of this modification on cell 
cycle proteins could cause cell cycle arrest. It remains to be determined whether 
D-GlcNAc has a direct modifying effect on cell cycle proteins or its effects on cell 
cycle progression are mediated via other intermediary proteins. Furthermore, 
more experiments are needed to rigorously test the contribution of the HBP and 
protein D-GlcNAc formation in vascular complications under normal and diabetic 
conditions. 
In chapter IV, we found that intermediary metabolism plays an important role in 
PDGF-induced phenotype transition. Specifically, we found that synthetic VSMCs 
show increased FAD and decreased rates of glucose oxidation (described in 
chapter III). This increase in FAD was preceded by changes in mitochondrial 
morphology. The increases in FAD may be required to meet the high energy 
demands of synthetic cells. 
In the synthetic state, VSMCs had mostly rounded or fragmented mitochondria 
compared with the long filamentous mitochondria found in contractile cells. It has 
been previously reported that filamentous mitochondria form giant networks that 
are associated with increased ATP production and that these networks can 
evade autophagic degradation under conditions of starvation. Here, however, we 
found that the fragmented mitochondrial phenotype may instead be associated 
with increased ATP production (since it utilizes more fatty acids). This increase in 
FAD in synthetic cells could be as a result of increased total mitochondria 
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surface area or increased expression (or activation) of proteins involved in FAO 
such as CPT1. The fragmented mitochondria (as well as increased FAO) 
contributed to VSMC hyperplasia because mdivi 1 (which promotes fusion) 
inhibited proliferation. These findings are consistent with previous studies 
showing that promoting mitochondrial fusion in VSMCs, by overexpressing the 
pro-fusion gene mitofusin, prevents VSMC hyperplasia, and that the fragmented 
mitochondria are predominant in diseased VSMCs such as found in hypertensive 
vessels [245, 256]. Inhibition of mitochondrial fragmentation also prevented 
increased FAO. This suggests that mitochondrial fragmentation is upstream of 
FAO observed upon PDGF stimulation. 
During mitosis, mitochondria fragmentation is required to produce equal 
mitochondria numbers for the emerging daughter cells. We found that inhibition 
of mitochondrial fragmentation caused cells to stall in the S-phase leading to 
inhibition of cell proliferation. This inhibition of cell proliferation could be attributed 
to: 1) the unavailability of mitochondria for the prospective daughter cells; and 2) 
the inhibition of FAO caused by mitochondrial fragmentation. In chapter IV, we 
present data supporting the latter because inhibiting FAO led to inhibition of cell 
proliferation. 
In summary, our results uncover novel mechanisms by which metabolism 
regulates VSMC phenotype. Our data identify autophagy as an important 
process regulating phenotypic switching and provide new insights into the role of 
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fatty acid metabolism in phenotypic transition. Although the metabolic and 
autophagic changes during this transition seem to occur via separate pathways, 
these pathways contribute to the emergence of a fully synthetic phenotype 
(Scheme 6). These data could form the basis for of the development of more 
effective anti-restenotic and -atherosclerotic therapies. Nevertheless, future 
studies are required to decipher the mechanism(s) involved in our observations. 
Studies aimed at determining the contributions of other substrates such as 
glutamine also warrant our attention, and in vivo studies are required to define 
the usefulness of chemical regulators of autophagy, O-GlcNAc and mitochondrial 
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APPENDIX 
NON-STANDARD ABBREVIATIONS AND ACRONYMS 
VSMCs Vascular smooth muscle cells 
SP-1 Spautin 1 
3-MA 3-methyl adenine 
USP Ubiquitin specific peptidase 
PDGF Platelet-derived growth factor 
HBP Hexosamine biosynthetic pathway 
GFAT Glutamine: Fructose amidotransferase 
UDP-GlcNAc Uridine diphospho-I3-N-acetylglucosamine 
O-GlcNAc 13-0-linked N-acetylglucosamine 
Ad-GFP Adenovirus-delivered green fluorescent protein 
Ad-GFP-LC3 Adenovirus-delivered green fluorescent protein linked LC3 
PUGNAc O-(2-acetamido-2-deoxy-d-glycopyranosylidene) amino-N-
phenyl carbamate 
OGT O-GlcNAc transferase 
LDH Lactate dehydrogenase 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 





















Mitochondria division inhibitor 1 
Extracellular matrix 
Osteopontin 
Fibroblast growth factor 1 
Microtubule-associated protein light chain 3 
Fatty acid oxidation 
Extracellular acidification rate 
Oxygen consumption rate 
4-hydroxy-trans-2-nonenal 
Carnitine palmitoyl transferase 1 
Low density lipoprotein 
Tricarboxylic acid cycle 
Koningic acid 
Mitochondrially encoded cytochrome c oxidase I 
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit 
ATP synthase subunit alpha 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 8 
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